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Cancer of the large bowel may be looked upon as a model of stepwise tumor development, as 
it has morphological distinct benign and malignant stages paralleling a preferential order of 
genetic and epigenetic aberrations. Despite being a well-investigated disease, close to half of 
the patients diagnosed with colorectal cancer die within 5 years. Testicular cancer on the other 
hand, which is the most common cancer among young males, represents a model for 
successful cancer treatment, due to its effective response to chemotherapy. The malignant 
tumors are in the triploid range but the underlying molecular changes initiating and promoting 
cancer in the male germ cell lineage remain mostly unknown. Malignant peripheral nerve 
sheath tumors are rare malignancies, which exhibit highly complex genomes. The disease is 
aggressive, with surgery as the only consensus for therapy. These three cancer types develop 
from three distinct germ layers, and changes common among them may be important for 
cancer in general. 
 
In the present thesis, we aimed to establish whether factors upstream of central signaling 
pathways, like the MAPK-, and PI3K-AKT-pathways1, are commonly altered in the 
abovementioned malignancies, and possibly also mutually exclusive, hence qualifying as 
master keys in cancer. KRAS, BRAF, PIK3CA, and PTEN were investigated for mutations by 
direct sequencing, whereas methylation-specific PCR was utilized to determine the promoter 
methylation status of RASSF1A. 
                                                 
1 See Appendix I for complete list of abbreviations and gene symbols/names approved by the Human Gene 
Nomenclature Committee; http://gene.ucl.ac.uk/nomenclature/ 
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In colorectal cancer, 80 % of the tumors examined were altered in one or more of the genes 
analyzed, and we identified a number of mutations in PTEN, previously not reported for this 
cancer type. Additionally, these mutations were associated with mutations in BRAF and 
microsatellite unstable tumors, and inversely associated with mutations in TP53.  
 
In testicular germ cell tumors only few mutations were identified, all in seminomas, whereas 
several non-seminomas contained promoter methylation of RASSF1A. Thus, our findings are 
in line with the view that gene promoter methylation is a more common mechanism than gene 
point mutations are during the development of this cancer type. However, large sequence 
changes such as chromosomal amplifications and deletions are also commonly found. 
 
Also among the malignant peripheral nerve sheath tumors, were few mutations found. 
Strikingly, however, about half of the tumors harbored promoter methylation of RASSF1A. 
Only few studies address promoter hypermethylation as a mechanism to inactivate genes in 
this malignancy, thus it remains to be seen if this is a more general mechanism in the 
development of the disease. 
 
Mutually exclusive events are found in key signaling pathways, suggesting that such 
alterations will have the same functional effect in the pathway. Here we have shown that 
mutations in KRAS and BRAF are inversely associated, implying that the mutations are 
equivalent when it comes to the tumorigenic effect. Furthermore, mutations in PTEN are also 
found to be inversely associated with alterations in KRAS, as well as with mutations in TP53. 
Promoter methylation of RASSF1A has previously been shown to be mutually exclusive to 
KRAS mutations. Our findings suggest the opposite, as we observed concomitant gene 
promoter methylation and mutations in the respective genes.  
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The MAPK- and PI3K-AKT pathways can be referred to as master keys, as they are found 
frequently altered in cancer. Indeed, we show that colorectal carcinomas are commonly 
altered in approximately 80% in one or more of the five genes analyzed from these two 
pathways. Furthermore, we support the hypothesis that the mechanism for development in 
TGCTs is gene promoter methylation, and finally, we have shown that RASSF1A is a factor 
with master key features in-as-much as it is altered in a significant portion of all three tumor 
diseases. However, further investigations needs to be done before conclusions can be drawn 
about how commonly the MAPK and PI3K-AKT pathways are affected, through which 
upstream factors and by which mechanisms this occurs in TGCT and MPNST. 
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Introduction to cancer biology 
 
Already 400 years BC the Greek physician Hippocrates, also entitled “the father of 
medicine”, described several types of cancer. This terminology includes a class of diseases 
characterized by uncontrolled division of cells that have escaped from normal regulatory 
mechanisms, which in turn give rise to tumors, or neoplasms. A neoplasia describes growth 
disturbance, and can either be benign or malignant. When the tumor cells have a slow growth 
rate, remain localized to their tissue of origin and do not spread to other sites in the body, the 
tumor is said to be benign. However, “cancer” generally refers to malignant tumors, which 
have severe defects in regulation of cell proliferation, invade surrounding tissue, and are able 
to spread to other organs to form secondary tumors, a process called metastasizing. Several 
lines of evidence indicate that tumorigenesis is a multi-step process and that these steps reflect 
genetic and epigenetic changes that drive the progressive transformation of normal cells into 
malignant cancers. 
 
Boveri was the first to propose a mechanistic basis to Mendel’s theories {Boveri T, 1914 83 
/id}. Based on his work on sea urchin eggs in the beginning of the 20th century, he discovered 
that the individual chromosomes carry different information, and he also described 
chromosomal abnormalities in neoplastic cells. Despite of rudimentary techniques and 
restricted knowledge of cell biology and genetics, Boveri managed to formulate what is now 
known as the somatic mutation theory of cancer. This theory implies that an acquired genetic 
change in a single somatic cell is the origin of a neoplasia, and this still holds the central stage 





In 1976, Nowell proposed that tumor development proceeds by a process called clonal 
selection, in accordance to darwinian evolution [2,3]. He stated that primary tumors are of the 
same unicellular origin, developed from the progeny of a single genetically unstable cell. As a 
result of this genetic instability, mutant cells are produced, and whereas nearly all of them are 
eliminated, occasionally one has gained an additional selective advantage and becomes the 
precursor of a new predominant population of clones that inherits the genetic and epigenetic 
alterations (see figure 1). A variety of experimental evidence supports the theory of 
monoclonality and clonal selection, making it the current dogma for tumor progression. 






Figure 1: Clonal selection. The classical view of cancer is that it arises through a series of genetic and/or 
epigenetic alterations, activating or inactivating oncogenes and tumor suppressor genes, respectively. As a result 
of the alterations, a monoclonal population of tumor cells acquires selective growth advantages on the expense of 




Ten to twenty percentages of cancers are classified as familial cancers due to familial 
clustering, however, the hereditary components are unknown (see figure 2). In contrast, 
although the inherited cancer syndromes cause approximately 5% of all cancers [6], molecular 
analyses of the affected genes have led to the discovery of new pathways and processes 
relevant to carcinogenesis. A major principle of cancer research is that the genes predisposing 
to the disease are usually somatically or epigenetically altered in sporadic cancer types as 
well. Numerous risk factors of cancer are known. In the cases having a sporadic origin  
(~ 90%), the interaction with environmental carcinogens including tobacco smoke, alcohol, 
diet, pollutants, and radiation as well as infectious agents, can in a combination with genetic 
and acquired susceptibility, be important [7-9]. Polymorphic variants of genes inactivated in 
inherited cancer syndromes may also predispose to sporadic cancer, in addition to ethnic 
background, gender, age, nutrition and preexisting health [10]. Cumulative lifetime exposure 
to carcinogens as well as accumulation of somatic mutations in aged cells might explain the 





Figure 2: The genetic and environmental contribution to cancer. Approximately 5% of all cancer cases are 
of hereditary origin, thus the genetic factors play a significant role. The majority of cancers cases are sporadic; 
the age of onset is generally higher than in the hereditary cases, and environmental factors are believed to be the 







The most basic function of the cell cycle is to replicate the vast amount of DNA in the 
genomes, and then segregate the copies precisely into two genetically identical daughter cells 
[11]. The eukaryotic cell cycle is generally divided into four phases (see figure 3). In the Gap1 
(G1) phase the cells monitor the extra- and intracellular signals that determine whether the 
cells will commit to replication and division or, alternatively, to exit the cell cycle into a 
quiescent stage, G0. The cells can reside in G0 for days or weeks, until conditions are 
favorable for resuming proliferation, or they may remain in G0 indefinitely like nerve cells do. 
Once the cells have committed to DNA replication by passing the Restriction point, (R) (see 
further down), the decision is irreversible. Following the G1 is the S-phase in which the DNA 
is synthesized, and G2, a growth phase. When the cells have doubled their mass of proteins 
and organelles, they enter the mitotic (M) phase where the actual segregation of DNA take 
place, followed by cell division [12]. The cell cycle transitions are regulated by protein 
complexes consisting of cyclin-dependent kinases (CDKs) and cyclins. The activity of these 
protein complexes is controlled by phosphorylation, dephosphorylation and interactions with 
CDK inhibitory proteins (CKIs), like p16INK4A and p27KIP1 [13]. In addition to the normal cell 
cycle components, there are regulatory processes termed checkpoints. These ensure proper 
replication of the DNA, as well as assembly of the mitotic spindle and completion of cell 
division. The abovementioned R-point in the G1/M transition is one of them. Cells containing 
damaged DNA are prevented from entering S-phase, and instead they enter cell cycle arrest. If 
the damage cannot be repaired, the cells undergo apoptosis, which prevents expansion of cells 
with inappropriate DNA, leading to mutations and carcinogenesis. The G2/M-checkpoint 




binding of chromosomes to microtubules [11]. The RB1- and TP53-network are important in 
regulation of the cell cycle, and at least one of them is believed to be inactivated in most, if 
not all, human tumors. This will be discussed further on page 25. 
 
 
Figure 3: The principle of the cell cycle and the main components involved. 
 
 
Milestones of cancer genetics and epigenetics 
Tracing the historical landmarks of cancer genetics and epigenetics from the transmission of 
traits proposed by Mendel to the present time, gives us a possibility to appreciate how far we 
have come in cancer research, but also makes us realize how challenging the translation of 
this knowledge into advanced medicine is. However, one of the most powerful tools in the 
fight against cancer is now within our grasp – the complete sequences of the human and 




Figure 4: Timeline of milestones in cancer genetics and epigenetics. Nature Milestones 2, [14,15] 







Boveri postulated the existence of “growth stimulatory chromosomes” [14]. The concept of 
the gene had not yet been introduced, but this prediction clearly foresaw the Nobel-prize-
winning discovery of cellular proto-oncogenes by Varmus and Bishop in the 1970s [16]. 
These highly conserved genes are present in all normal cells, in which they have important 
regulatory functions. Proto-oncogenes typically encode proteins involved in positive control 
of the cell cycle, such as growth factor receptors, signal transduction proteins and 
transcription factors. When altered, they tend to relax control mechanisms increasing the rate 
of growth and division, and can thereby transform a normal cell into a neoplastic cell. The 
alteration of the normal functioning proto-oncogenes into an over-active oncogene can be 
quantitative (e.g. a point mutation or deletion) or qualitative (by gene amplification or 
chromosome rearrangement). Either way, the alterations are dominant, meaning that mutation 
in one allele is sufficient to transform a proto-oncogene into an oncogene. 
 
Tumor suppressor genes  
Knudson discovered the first tumor suppressor gene in the early 1970s when he carried out an 
epidemiological study of retinoblastoma development in children [17].  He postulated that 
“two hits” are required for the complete inactivation of anti-oncogenes, later renamed to 
tumor suppressor genes. In 1983 Cavenee and colleges used the principle of loss of 
heterozygosity (LOH) analysis to test Knudson’s hypothesis and to map the RB1-gene [18]. 
Even though the discovery of tumor suppressor genes arose from examination of a single 
disease, it turned out to be of universal relevance. Tumor suppressor genes (TSGs) are a class 




cancer-preventive effects usually require the presence of only one functional allele, the TSG 
typically act recessive, as postulated in Knudson’s “two hit hypothesis”. Both alleles have to 
be affected, usually achieved by inactivation of one allele by a vast chromosomal event, (such 
as loss of a chromosome arm or an entire chromosome,) coupled with an intragenic mutation 
or epigenetic inactivation of the other allele [19,20]. However, there are several known 
examples of haploinsuffiency – in which functional loss of only one allele confers a selective 
advantage for tumor growth [21] One well defined example involves the Cdk inhibitor p27 in 
mice [22]. The numbers of haploinsufficient tumor suppressors are increasing, and genes like 
TP53, ARF and PTEN have also shown such effects, particularly when combined with 
collaborating mutations affecting additional oncogenes or tumor suppressors [23]. The protein 
products of TSGs are typically involved in monitoring replication of DNA, progress of the 
cell cycle, and in promoting repair of damaged DNA, hence reduced expression or 
inactivation contributes to malignancy. 
 
DNA repair genes 
The integrity and survival of a cell is dependent on genome stability. Mammalian cells 
therefore have highly conserved DNA damage sensor mechanisms, which can activate several 
cellular responses that determine cell fate like DNA repair and apoptosis [24]. These 
checkpoints are encoded by DNA repair genes, a type of TSGs that keep the genetic 
alterations in the cell at a minimum. Hence inactivation of these genes can lead to a higher 
mutation rate in the genome. As with the other TSGs, both alleles of the DNA repair genes 
have to be inactivated to cause a physiological effect. One of the known repair systems of 
particular relevance for colorectal tumorigenesis is the mismatch repair (MMR) system. In 
human cells, MSH2, MSH3, and MSH6 among others, participate in the process where base-




degrades the section of error in the newly synthesized strand and gives the polymerase 
another chance to generate a strand free of errors. In the absence of MMR, base-base 
mismatches remain uncorrected resulting in a mutator phenotype that is accompanied by 
microsatellite instability and eventually, cancer (see page 40). 
 
Epigenetics 
Epigenetic inheritance is defined as cellular information other than the DNA sequence itself, 
that is heritable during cell division [15]. Since the discovery of its relevance in cancer in 
1983 [26,27], this field has gradually gained more scientific attention, resulting in a better 
understanding of specific epigenetic mechanisms and their role in cancer. In general, there are 
three main types of epigenetic modifications: DNA methylation, histone modification and 




The best-known epigenetic modification is DNA methylation, which in general is associated 
with transcriptional inactivation. Methylation is transfer of a methyl group (-CH3), using the 
S-adenosyl-L-methionine (SAM) as a donor, to the C-5 position in a cytosine ring. The 
conversion of cytosine to 5-methylcytosine is catalyzed by a family of DNA methyl 
transferases [28]. Methylation occur most frequently at cytosines located 5’ to a guanine, in a 
so-called CpG site. DNA stretches of typically 0.5-4 kb, with a GC content of more than 55%, 
constitute CpG islands which contain approximately 20% of all CpG dinucleotides in the 
genome [28]. Such CpG islands can be found in about half of all mammalian genes and are 




not undergo methylation due to protective boundary elements, whereas CpG dinucleotides not 
associated with CpG-islands are heavily methylated [28,29]. Methyl-DNA-binding domain 
proteins and histone deacetylases specifically recognize the modified sequences and attract 
large multi-protein complexes that can change the chromatin conformation from an open to a 
closed state, and hence lead to gene silencing [30]. 
 
DNA methylation in the normal cell 
DNA methylation levels change in a highly orchestrated way during mammalian 
development. A well-regulated process around the gastrulation stage of embryogenesis 
establishes the global methylation patterns characteristic of genomic DNA of adult somatic 
tissues. During cleavage of the zygote, a wave of genome-wide demethylation removes the 
epigenetic modification, so that the DNA of the blastocyst is highly hypomethylated. Before 
implantation, a wave of global de novo-methylation re-establishes an overall methylation 
pattern, which is maintained through life. After gastrulation, this pattern does not change 
substantially. In the normal cell, DNA methylation can be found in imprinted genes, x-
chromosome genes in women, germ-line specific, and tissue-specific genes (see figure 5) 






Figure 5: The influence of DNA methylation in normal cells and cancer cells. Modified after Esteller et al, 
ref. [32]. 
 
DNA methylation and cancer  
Tumor development is typically characterized by a number of epigenetic alterations (see 
figure 5), including a general hypomethylation across the genome as well as gene specific 
hypermethylation. Hypomethylation, meaning loss of DNA methylation in CpG 
dinucleotides, was the first epigenetic abnormality to be identified [26]. Recent studies have 
demonstrated that this hypomethylation can increase genomic instability by removing the 





Although hypomethylation was the first epigenetic change identified in cancer, more attention 
has been focused on hypermethylation. In 1986, Baylin and co-workers found site-specific 
hypermethylation of calcitonine, with consequent silencing of calcitonine expression [15]. 
However, the first link between tumor suppressor genes and hypermethylation was made with 
the retinoblastoma-gene, RB1 [19,20]. In the wake of that discovery, the potential impact of 
inactivation of tumor suppressor genes in cancer development by DNA hypermethylation was 
realized. The aberrant methylation of TSGs appears to occur early in tumor development and 
increases progressively, eventually leading to a malignant phenotype. In summary, cancer is 
today considered to be both a genetic and epigenetic disease. 
 
Hallmarks of cancer 
Cancer is a disease involving continually changes in the genome. In a review from 2000, 
Hanahan and Weinberg argue that the complexity in the development of the disorder can be 
narrowed down to 6 essential alterations in cell physiology [34]. To be able to grow at the 
expense of other cells, cancer cells must acquire some capabilities that give them selective 
growth advantages, including self-sufficiency in growth signals, insensitivity to anti-growth 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis. In addition, it has recently been pointed out that stem cell capabilities 





Self-sufficiency in growth signals  
Growth signals are required for the proliferation of all cells. Tumor cells generate many of 
their own signals, and thereby reduce their dependence on stimulation from their normal 
tissue microenvironment. Three molecular strategies for achieving this include alteration of 
extracellular growth signals, altered activity of cell surface receptors that transduce the 
growth-stimulatory signals or modifications of components in the downstream intracellular 
pathways that receive and translate the signals into action [34]. 
  
Insensitivity to anti-growth signals  
To maintain tissue homeostasis and cellular quiescence, multiple anti-proliferative signals are 
in action. These signals force cells into G0, the quiescent state, or induce them to differentiate 
so they are unable to proliferate further. In order to evade this, disruption of a component in 
the RB-pathway is an option. Many anti-proliferative signals are directed through the RB1-
protein and two of its relatives, p107 and p130. Hypo-phosphorylated RB1 binds to and 
inhibits the E2F-transcription factors that, when unbound, control the expression of genes 
necessary for progression from G1 to S-phase in the cell cycle. Altering components in the 
pathway or phosphorylaton of RB1 itself, releases the E2Fs, and hence the cell is insensitive 
to anti-growth signals [36].  
 
Evasion of apoptosis 
It is believed that all cells harbor a latent program for cell death where they die without 
damaging their neighbors; the cell shrinks and becomes engulfed by nearby cells. Activation 
of the intracellular cell death pathway is usually triggered in an all-or-none fashion [11]. Once 




between proliferation and apoptosis are carefully supervised to maintain the proper number 
and types of cells. Apoptosis is also a mechanism to remove cells with severe DNA damage 
and can be triggered by a variety of stimuli, from overexpression of oncogenes, withdrawal of 
essential survival signals, and activation of death signals. The machinery can be divided into 
sensors and effectors where the sensors are responsible for monitoring the extra- and 
intracellular environment for harmful conditions. These signals regulate the effectors, which 
start the cell death program. Mutation of the tumor suppressor gene TP53 is one of the most 
frequent alterations observed in human tumors. An aberration in this protein can affect the 
ability of sensors to regulate the effectors, since several signals are funneled in part via TP53 
[37]. It is expected that virtually all cancer cells harbor alterations that makes them capable of 
evading apoptosis [34]. 
 
Limitless replicative potential 
The central dogma in cell biology stated that normal human cells could replicate indefinitely. 
It was not until Hayflick in the 1960s demonstrated that cells in culture could only divide a 
limited number of times, approximately 50, the dogma was changed, and the phenomenon 
termed cell senescence. The limited proliferation capacity reflects a progressive shortening of 
the cell’s telomeres, the repetitive DNA sequences and associated proteins that cap the ends 
of each chromosome [11]. Fifty to hundred telomeric base pairs tend to be lost from the 
chromosome end each cell cycle. Unprotected chromosomes make end-to-end fusions with 
cell death as an expected outcome. Human somatic cells have turned off the enzyme that 
normally maintains the telomeres, telomerase. In order to gain a limitless replicative potential 
and to transform, the cancer cells have to up-regulate the telomerase activity, or circumvent 





Sustained angiogenesis  
All human cells require a secure, controlled supply of oxygen. Since the diffusion of oxygen 
through tissues is limited, a vascular system has evolved to make sure that all cells are within 
the maximum distance of a capillary blood vessel [38]. Once a new tissue is formed, the 
growth of new blood vessels – the process of angiogenesis – is carefully regulated. 
Angiogenesis is subject to a complex control system with proangiogenic and antiangiogenic 
factors and normally, there is a strict regulation of the physiologic balance between these 
stimulatory and inhibitory signals. In order for tumors to reach a significant size, they have to 
acquire angiogenetic abilities, which is usually done by activating an angiogenic switch by 
changing the balance of inducers and inhibitors. One way to achieve this involves alteration 
of gene transcription. The ability to induce and sustain angiogenesis is found to be an early 
event in tumor development [39], and is therefore an attractive therapeutic target. Remarkable 
and very promising tumor growth suppression has been observed in animal models using 
several antiangiogenic approaches [38]. 
 
Tissue invasion and metastasis 
Metastasis, the spreading of cancer cells in the organism, is the most lethal aspect of cancer 
development. There are many factors playing a crucial role in this complex process, including 
somatic mutations, epigenetic modulation, interaction with normal stroma, and environmental 
stimuli. Additionally, recent evidence implies a significant role for germline polymorphisms 
in cancer progression [40]. The capability for invasion and metastasis enables cancer cells to 
escape from the primary tumor, enter blood- or lymph vessels, and colonize somewhere else 
where nutrients and space is not a limiting factor. A strategy to make this possible often 
involves changing the physical coupling of cells to their microenvironment. Several classes of 




interactions and integrines which link cells to the extracellular matrix, are the most frequently 
changed. One commonly seen alteration involves the cell-to- cell adhesion molecule, E-
cadherin, encoded by the CDH1 gene. This protein is usually embedded in two adjacent 
plasma membranes to bind epithelial cells together. When tumors have made this gene or 
protein inactive, it favors metastasis by specifically contributing to local invasiveness [11]. 
 
Cancer critical genes and the signal transduction pathways they 
are part of 
The genes selected for the present study are important components of signaling pathways 
frequently altered in cancer. The next few pages will give a short description of some of the 
central pathways, as well as a description of the selected genes and their role in cancer 




Figure 6: Cancer critical pathways, a general overview. The figure illustrates the WNT, receptor tyrosine 
kinase/MAPK, PI3K/AKT, and TGF-β signaling pathways. Genes investigated in this thesis, are marked with a 
dashed, white circle. 
 
 
Signaling pathways important for homeostasis are often deregulated in cancer. In the last 
decade, several genes responsible for the origin of various cancer types have been discovered, 




have shown that the mutations within one pathway sometimes obey an “exclusivity 
principle”. That is, only one or a few genes in a pathway are generally mutated in any single 
tumor, since the functional effect of each mutation is similar [41]. The discovery and 
delineation of these highly conserved signal transduction pathways represent major scientific 
success stories as they have huge practical implications. The fact that defects in a relatively 
small number of pathways underlies various tumor types suggest that targeted therapeutics 
will be effective against a broad range of cancers. 
  
The RB1 and TP53 pathways 
Virtually all DNA viruses that cause tumors in experimental animals or humans, encode 
proteins that inactivate both RB1 and TP53 [41]. (See page 23 for overview figure). Why have 
these two been singled out as targets for inactivation? In part, it may be impossible for a 
tumor of epithelial origin to form, unless the TP53 and RB1 tumor suppressor gene pathways 
are non-functioning. This is supported by numerous studies, reporting that these two pathways 
are altered in a large fraction of cancers [41]. RB1 and TP53 are central to several processes 
and alterations can disrupt normal growth control in response to environmental signals, 
inactivate cell cycle checkpoints that otherwise limit cell division, or induce apoptosis in 
response to DNA damage or oncogene activation [42]. The control of G1- progression and S-
phase initiation in the cell cycle is often disrupted in cancer cells. Components of the 
transcription factor protein family, E2F, normally bind to specific DNA sequences in the 
promoters of many genes encoding S-phase entry proteins. E2F function is controlled mainly 
by the interaction with RB1-protein, which is an inhibitor of cell cycle progression. During 
G1, RB1 binds to E2F and blocks the transcription of S-phase genes. When cells are 
stimulated to divide by extracellular signals, active G1-Cdk accumulates and phosphorylates 




activate S-phase gene expression (Figure 3) [11]. This is also what happens when RB1 or 
some of the other components in the pathway become altered.  
 
The TP53 pathway is composed of a network of genes and their products, which respond to a 
variety of stress signals that have an impact on cellular homeostatic mechanisms. An 
activating stress signal is transmitted to the TP53 protein, which is working as a transcription 
factor. Thereby it initiates a program of cell cycle arrest, cellular senescence and/or apoptosis 
[43]. Because TP53 normally interacts with another protein, MDM2, it is highly unstable and 
present at very small concentrations. MDM2 acts as an ubiquitin ligase, and targets TP53 for 
degradation by the proteasome. A DNA damage in the genome will activate protein kinases 
that phosphorylate TP53 and thereby reduce its binding to MDM2. This decreases TP53 
degradation, and subsequently enhances its ability to stimulate gene transcription [11]. The 
transcriptional network of TP53-responsive genes produces proteins that interact with a large 
number of other signal transduction pathways, resulting in many positive and negative 
autoregulatory feedback loops that act upon the TP53 response [43]. A point mutation in the 
DNA binding domain that inactivates the ability of TP53 to bind to its recognition sequence is 
the most common way to disrupt the TP53 pathway. However, there are several other ways 
that achieves the same effect, including amplification of the MDM2 gene. 
 
The canonical Wnt signaling pathway 
Wnt-proteins are molecules released from the surface of signaling cells, which act as local 
mediators to control many aspects of normal development. (See page 23 for overview figure.) 
They are among others required for maintenance of adult tissue, hence disturbances in Wnt 
signaling can promote both human degenerative diseases and cancer [44]. The Wnt-proteins 




of the Frizzled family and low-density lipoprotein receptor-related protein, LRP. They 
transduce signals to several intracellular proteins, including the signaling protein Dishevelled. 
The Dishevelled-dependent pathway regulates proteolysis of the protein β-catenin, encoded 
by the CTNNB1 gene, which functions both in cell-cell adhesion and as a latent gene 
regulatory protein. In the absence of Wnt signaling, most of the β-catenin is located at cell-
cell adherens junctions, and those molecules that are not, are rapidly degraded in the 
cytoplasm [11]. The proteasome-mediated degradation is controlled by a complex containing 
the serine/threonine kinase glycogen synthase-3β (GSK-3β), the tumor suppressor protein 
adenomatous polyposis coli (APC) and the scaffold protein Axin. GSK-3β phosphorylates β-
catenin thereby marking it for ubiquitylation, APC helps promote degradation by increasing 
the affinity of the degradation complex for β-catenin, whereas Axin holds the protein complex 
together. When cells receive Wnt signals, phosphorylation and degradation of β-catenin is 
inhibited, and as a result, it accumulates in the cytoplasm and nucleus [45]. Nuclear β-catenin, 
now working as a coactivator, interacts with transcription factors such as lymphoid enhancer-
binding factor 1/T-cell specific transcription factor (LEF1/TCF) that induce the transcription 
of Wnt target genes. Among the genes activated is MYC, which protein product is a strong 
stimulator of cell growth and proliferation, JUN, and CCND1[11]. Also a large number of the 
components in the Wnt signal transduction pathway itself are found to be targets of Wnt, 
hence providing feedback control during signaling [44]. Mutations of the APC gene occur in 
60-80% of human colorectal cancers [46]. The effect is inhibition of the protein’s ability to 
bind to β-catenin, so that, even in the absence of Wnt signaling, it accumulates in the nucleus 
and induce transcription of MYC and the other Wnt target genes. As a consequence, 
uncontrolled cell proliferation promotes the development of cancer [11]. Also other 
components in the cytoplasmic complex may be mutated in addition to or exclusively to APC, 




Receptor tyrosine kinase signaling 
The signals conveyed by soluble growth factors, hormones and cytokines, required for 
survival and proliferation, are transmitted into the cell by transmembrane proteins with 
tyrosine kinase activity. (For overview figure see page 24.) The receptor tyrosine kinases are 
currently classified into 19 structural subfamilies, each dedicated to bind its complementary 
family of protein ligands [48]. Binding of a signal protein activates the intracellular tyrosine 
kinase domain of the receptor and makes it undergo receptor dimerization and 
autophosphorylation (See figure 7). This recruit adaptor proteins like GRB2, SHC1 and the 
guanine nucleotide exchange factor (see below) SOS1, which further interact with and 
activate various downstream effectors. An important component of the growth factor-RTK 
signaling pathway is the small GTP-binding protein, KRAS, which can activate several 
downstream cascades. The growth factor-RTK-RAS signaling pathway is one of the most 
frequently targeted genetic pathways in human cancers (~30%) [49], probably because 






Figure 7: The MAPK-pathway. Ligand binding to receptor tyrosine kinases (RTKs) results in dimerization and 
autophosphorylation. This recruits the adaptor-protein GRB2 and the guanine nucleotide exchange factor SOS1, 
which activates KRAS. By associating with its RAS-binding domain, KRAS activates BRAF, which in turn 
activates the MAP-kinase-cascade, resulting in changes in gene expression. 
 
KRAS 
The ras gene family encodes highly related proteins involved in signal transduction. They 
belong to a family of membrane-bound GTP-ases cycling between to stages, a GDP-bound 
and a GTP-bound state. The cycle is controlled by guanine nucleotide exchange factors 




inactive GDP-Ras, respectively [11]. Activating mutations are found in a wide range of 
human diseases, and represent some of the most frequently mutated oncogenes in cancer, 
indicating that the proteins have a powerful transforming potential. [50] The best-known 
effectors of RAS is the RAF-family, which serves to regulate the mitogen-activated protein 
kinase (MAPK) cascade activated by growth factors (See figure 7) [50]. 
  
KRAS mutations in cancer 
KRAS, located on chromosome 12p, is the ras gene where the majority of transforming 
mutations is found, typically in codon G12, G13 and Q61 [51]. Point mutations in these hot 
spots produce a protein unable to hydrolyze its bound GTP, thereby bringing it into a 
perpetually active state. This leads to excessive and inappropriate signaling, promoting 
cellular transformation. The spectrum of tumor types showing KRAS mutations is broad, 
including pancreatic cancer (72-90%) [52], colorectal cancer (32-57%) [52,53], and testicular 
cancer (9-12%) [54]. KRAS serves as a node for a wide range of signal transduction pathways 
including the MAPK, PI3K-AKT, JNK and CDC42-RAC1-RHO pathways [55]. 
  
BRAF  
BRAF encodes one out of three cytoplasmic serine/threonine kinases in the RAF-family, and 
is normally regulated by mitogens like growth factors, cytokines and hormones, which bind to 
and activate RTKs and G-protein-coupled receptors on the cell surface [56]. These receptors 
activate RAS, which in turn activates BRAF by binding to its RAS-binding domain. BRAF 
activates a second protein kinase, MAP2K1, which subsequently activates a third protein 
kinase, called MAPK1. This pathway, working through MAPK1, regulates gene expression, 
cytoskeletal rearrangement and other kinases, which in turn control senescence, apoptosis, 




active, thereby stimulating the MAPK-pathway and hence cell growth, independently of 
mitogenic signals.  
 
BRAF mutations in cancer 
Most of the mutations found in BRAF are encompassed in exon 11 and 15, which represent a 
glycine rich loop and a kinase domain, respectively. The alterations seems to involve many of 
the residues that stabilize the interaction between these two regions [57]. Occurring in 90% of 
the cases, V600E, substituting a valine residue by a glutamic acid, is the most common 
mutation in BRAF [58]. The V600 mutation, residing in exon 15, can also be converted to 
other amino acids, although at very low frequencies. Mutations in this codon overcome the 
need for a RAS-dependent step since insertion of an acidic residue at position V600 is 
believed to render a negative charge to the amino acid which mimics activation loop 
phosphorylation of T599/S602 in wild type BRAF, thus causing it to be constitutively active 
[59]. BRAF mutations are common in many cancers, but there is a trend towards the 
occurrence of mutations in cancer types known to be mutated in RAS, including malignant 
melanoma, colorectal cancer and borderline ovarian cancers [59]. However, concomitant 
mutations are extremely rare, suggesting that mutations of BRAF and RAS are mutually 
exclusive genetic events and that activation of the MAP-kinase signaling pathway can be 
achieved by mutations at various levels in the cascade [57] [60]. 
 
RASSF1A 
The RASSF1 gene was first discovered as recently as in 2000 [61] [62]. By differential 
promoter usage and splicing, it encodes seven transcripts, whereupon two isoforms, A and C, 
are ubiquitously expressed. They are members of a new group of RAS effectors that is thought 




TSGs has been shown to be as commonly caused by epigenetic events as by mutation/deletion 
events. RASSF1A falls in to this category. Chromosome band 3p21.3, containing the RASSF1, 
is found to frequently undergo loss of heterozygosity in tumors, and if the remaining band is 
methylated [61], RASSF1A obey Knudson’s two hit model for inactivation of TSGs. A part of 
RASSF1 is homologous to the RAS-effector protein NORE1, and encodes a RAS-association 
domain (see figure 8). 
 
 
Figure 8: The structural domains of RASSF1A. 
Abbreviations: bp, base pair; aa, amino acids; DAG, phorbol ester/diacylglycerol-type binding domain; RAS, 
RAS association binding domain; SARAH, SAV/RASSF1/HPO interaction domain; ATM, putative ATM 
phosphorylation site. 
 
Several studies have begun to investigate the biochemical function of RASSF1A, but we are 
still far from understanding its true role. Apparently it is involved in several growth 
regulatory and apoptotic pathways, (See figure 9). Data indicate that binding of RASSF1A to 
GTP-bound RAS may require heterodimerization with NORE1, and that RASSF1A itself can 
bind RAS only weakly, if at all [64]. Recent research indicate that activation of KRAS and 
inactivation of RASSF1A and NORE1 may be a mutually exclusive event in colorectal and 
pancreatic cancers, providing alternative ways of affecting RAS signaling [65]. The pro-
apoptotic kinase MST1 is found to bind both RASSF1A and NORE1, indicating that this 
complex formation mediate the apoptotic effect of activated KRAS [66]. Shivakumur and co-
workers have reported that RASSF1A can induce cell cycle arrest by engaging the RB-family 
cell cycle checkpoint both directly and indirectly. RASSF1A inhibited accumulation of cyclin 




implies that RASSF1A modulates cell cycle progression through pathways regulating 
accumulation of cyclin D1 protein [67]. Recently, several groups have reported that 
RASSF1A might regulate mitotic progression due to the findings that it is a microtubule-
binding protein [68]. It has also been reported that it can regulate mitosis by inhibiting the 
anaphase promoting complex (APC) through CDC20 and induces G2/M arrest at pro-
metaphase [69]. Thus, RASSF1A function as a tumor suppressor through controlling 
apoptosis and mitotic cell division. 
 
Figure 9:  Summary of the putative RASSF1A network. RASSF1A can regulate apoptosis, the microtubule 
network and cell cycle progression by interaction with NORE1 and recruitment of various effectors. Modified 




RASSF1A in cancer 
Mutations of RASSF1A are rarely found in tumors. However, silencing of RASSF1A by 
promoter hypermethylation is a common event associated with a wide range of human 
malignancies including lung cancer, breast cancer, renal cell carcinomas, ovarian, gastric and 
bladder cancers [63]. 
 
 The phosphatidylinositol- 3-kinase – AKT pathway 
The phosphatidylinositol 3-kinase (PI3K) pathway regulates various cellular processes, such 
as proliferation, cell growth, cytoskeletal rearrangements, and apoptosis. (See page 23 for 
overview figure). The PI3Ks are members of a large and complex family containing three 
classes consisting of multiple subunits and isoforms. The proteins are heterodimeric lipid 
kinases composed of regulatory and catalytic subunit variants encoded by separate genes and 
alternative splicing [71]. Class IA PI3Ks are activated by receptor tyrosine kinases or by 
binding of active RAS to the p110 catalytic subunit. The primary consequence of activating 
PI3K is generation of the second messenger phosphatidylinositol 3,4,5 triphosphate (PIP3), 
using phosphatidylinositol 3,4 diphosphate (PIP2) as a substrate (see figure 10) [72]. Frequent 
genetic aberrations in the PI3K-pathway have been detected in several types of human cancers 
[73]. AKT1, (also known as PKB), a serine/threonine kinase, which acts downstream of PI3K, 
regulate various biological processes, including those involved in tumor development and 
progression [71]. AKT1 is recruited to the plasma membrane, and becomes activated through 
direct contact with a pleckstrin-homology (PH) domain with PIP3. Also other components in 
the pathway are involved in tumorigenesis. Amplifications as well as deletions of short 
nucleotide sequences of the PI3K locus have resulted in elevated levels of lipid kinase 
activity. This implies that PI3K functions as an oncogene [74]. Alterations in the PIK3CA 




liver, stomach and the lungs [71]. The phosphatase PTEN, which is also altered in a wide 
range of tumor types, counteracts the kinase activity of PI3K by dephosphorylation, thereby 
suppressing growth [75]. (See also page 37). The clinical evidence of PI3K-pathway 
deregulation in various cancers and the identification of downstream kinases involved in 
mediating the effects of PI3K (AKT1, MTOR, PDK1, ILK) provide present and potential 




Figure 10: The PI3K – AKT signaling network. Ligand binding to receptor tyrosine kinases or activated 
KRAS activates PI3K, which phosphorylates PIP2 converting it to PIP3. This action can be reversed by 
dephosphorylation carried out by PTEN. Through recruitment and interaction with PIP3 and phosphorylation by 
PDK, AKT1 becomes activated and mediates the activation and inhibition of several targets, resulting in cellular 





PIK3CA, which encodes the catalytic p110α subunit of PI3K, is located on chromosome 3, 
and encodes 20 exons [76]. 
 
PIK3CA mutations in cancer 
Gene amplifications, deletions, and more recently, somatic missense mutations of PIK3CA 
have been reported in 15% of human cancers. Especially cancers of the liver, breast, and 
colon is found to have a high rate of these mutations, with the approximate frequencies of 36, 
26 and 25%, respectively [71]. Mutations can be found spread throughout the whole sequence 
of the gene, but are primarily clustered in the helical and kinase domain, located to exon 9 and 
20. The most frequently altered residues are the glutamates E542 and E545, most often 
substituted by lysine, and histidine H1047, which becomes substituted by an arginine. These 
three hot spots are highly conserved in evolution, and are therefore likely to play a significant 
role for the functioning of the gene [71]. Indeed, at all three sites, the mutations cause gain of 
enzymatic function [77]. In addition, studies have shown strong evidence for the oncogenic 
potential of the mutant proteins, which can induce oncogenic transformation when expressed 
in primary chicken-embryo fibroblasts and NIH3T cells [73,78]  
 
PTEN 
Phosphatase and tensin homologue deleted on chromosome ten (PTEN), also known as 
MMAC1, encodes a dual specificity phosphatase. The gene product dephosphorylates tyrosine 
and serine/threonine residues on both proteins and lipids [79], and is found both in the 




PTEN in cancer 
Several studies demonstrate high levels of PTEN mutations or deletions in various human 
cancers, including brain, bladder, breast, prostate and endometrial cancers, as well as in the 
cancer predisposition syndrome Cowden disease. This makes PTEN the second most 
frequently mutated tumor suppressor gene after TP53 [82] [83]. The major task for PTEN is 
regulation of PIP3 levels. By dephosphorylating PIP3, it inhibits the growth factor signals 
transduced through PI3K. The loss of PTEN results in increased concentrations of PIP3, 
which in turn activates several signaling molecules, including AKT1, MTOR, 
phospahtidylinositol dependent kinases (PDKs) as well as the small GTPases RAC1 and 
CDC42 [82]. In other words, PTEN is exerting its tumor suppressor function through negative 
regulation of the PI3K-AKT pathway, which also interacts with other signaling cascades like 
TGFβ/SMAD and the WNT/β-catenin pathways. It has been shown that PIK3CA and PTEN 
can be mutually exclusive, suggesting that tumorigenic signaling through the PI3K- AKT1 
pathway can occur either through activation of PIK3CA or by inactivation of the tumor 
suppressor PTEN [71]. It has been proposed that PTEN-controlled pathways are involved in 
regulation of stem cell renewal, cell fate determination, and cell and organ size by controlling 
cell cycle checkpoints and hormones. However, more studies are required to find the exact 
and complete biological function of PTEN [82]. 
 
TGF-β signaling pathway 
Transforming Growth Factor β (TGF-β) signaling is regulating a diverse set of cellular 
processes, including cell proliferation, differentiation, apoptosis, and specification of 
developmental fate [84]. TGF-β superfamily members signal through receptor 
serine/threonine kinases and intracellular Smad-proteins. Additionally, several intracellular 




coupled receptors also participate in the TGF-β signaling network, however, the canonical 
Smad pathway is the most commonly mentioned in regard to TGF-β. (See page 23 for 
overview figure.) It is evolutionary conserved, and of great importance for the precise 
implementation of the tissue- and organ-patterning programs during development [85]. TGF-β 
binding induces the formation of a serine/threonine kinase complex consisting of TGF-β 
receptor type II (TGFβRII) and receptor type I (TGFβRI.) The constitutively active TGFβRII 
kinase phosporylates TGFβRI within a regulatory region, resulting in its activation. Then, 
TGFβRI phosphorylates receptor-activated (R)- SMADs. The phosphorylated (R)- SMADs 
form complexes with the common mediator SMAD4, enter the nucleus where they bind to 
DNA and interact with transcription factors to regulate gene expression [86]. The importance 
of the TGF-β pathway as a growth repressor has been demonstrated by the disruption of the 
signaling components in human cancers, contributing to tumorigenesis. Mutations have been 
observed both in TGF-β receptor family and the SMAD-proteins [84]. 
 
Development of solid tumors 
The tissues of the adult vertebrate body are generated from three germ layers established 
during gastrulation. Some cells cohere to create an epithelial sheath facing the external 
environment, the ectoderm, which is a precursor to the epidermis and the nervous system. A 
part of the sheath becomes tucked into the interior to form endoderm, the precursor of the gut 
and the internal organs, such as lungs and liver. A third group of cells move into the space 
between the endoderm and the ectoderm, and makes up the mesoderm, which gives rise to 







Figure 11: Gastrulation. Development of ectoderm, endoderm and mesoderm, which eventually will make up 
distinct tissues. Modified after Alberts et al, ref. [11]. 
 
 
Cancers are classified according to the tissue and cell type from which they arise. The most 
common cancer types arise from the epithelial cells, are termed carcinomas and include 
breast, prostate, lung, and colon cancer. Cancers arising from connective tissue or muscles are 
termed sarcomas [87]. The classifications of central neurological tumors are based on their 
predominant cell types, e.g. astrocytoma is composed primarily of astrocytes and 
oligodendroglioma primarily of oligodendrocytes. In the peripheral nervous system, most of 
the tumors are termed neurofibromas [55]. 
 
Development of the germ cell lineage is independent of the three germ layers. A group of 
cancers termed germ cell tumors are believed to arise from primordial germ cells. They 
represent a heterogeneous group of neoplasms, which arise in gonads, both in the ovaries and 
the testes. Additionally, this tumors can in rare cases be found in various extragonadal sites 





Colorectal cancer (CRC) is one of the most common cancer types, and represents the fourth 
most frequent cause of cancers deaths, worldwide [89,90]. The adenoma-carcinoma sequence 
is the basis for the development, and several underlying molecular changes have largely been 
identified. New information in this field has led to the development of targeted therapeutic 
options, which are being tested in clinical trials [90]. 
 
Epidemiology 
The World Health Organization (WHO) has estimated that every year, nearly one million 
people worldwide develop colorectal cancer, of which almost 50 percent die within 5 years 
[91]. Norway has the highest incident of colorectal cancer among the Nordic countries, with 
approximately 3500 new cases each year3. This cancer is less common in developing than in 
developed countries, and in the latter group, colorectal cancer is the second most common 
tumor, with a lifetime incidence of 5%. However the incidence and mortality are now 
decreasing [92]. Most cases of colorectal cancer are sporadic, and genetic, epigenetic, and 
environmental factors are all believed to play a role both in the initiation and the progression. 
About 10-20% of all patients with this cancer are estimated to have a familiar risk without 
fulfilling the criteria for hereditary colorectal cancer [93], whereas 5-10% develop in the 
setting of defined hereditary cancer syndromes.  High-penetrance mutations confer 
predisposition to hereditary non-polyposis colorectal cancer (HNPCC), which involves 
mutations in mismatch-repair genes, and to familial adenomatous polyposis coli (FAP), which 
involves mutations in the APC  (Adenomatous Polyposis Coli) TSG. Patients with chronic 
inflammatory bowel diseases like Ulcerative colitis and Crohn’s colitis or hamartomatous 
                                                 




polyposis syndromes, including Peutz-Jeghers syndrome and Cowden syndrome, also have an 
elevated risk of developing colorectal cancer [90]. 
 
The adenoma-carcinoma sequence 
The well-defined sequence of events during colorectal cancer development, suggested by 
Muto and co-workers in 1975 [94] – from aberrant crypt foci to benign adenomas, further on 
to carcinoma in situ, and finally to metastatic carcinomas – reflects the stepwise accumulation 
of histological and concurrent genetic and epigenetic changes (See figure 12). It might take 
several decades to develop these tumors, however, as a result of the relative ease with which 
the various stages can be observed, colorectal cancer provides an excellent model for cancer 
development. It has been found that somatic mutations occur, at least to some extent, in a 
predictable order during the sequence. The earliest genetic mutations detected in precursor 
lesions of sporadic colorectal cancer, as well as in carcinomas, are APC and KRAS, which is 
found to be mutated in 60-80% and 50% of the carcinomas, respectively [46].  
 
 
Figure 12: The adenoma-carcinoma sequence; genetic and epigenetic characteristics of the microsatellite 




Colorectal carcinomas can be classified into two main phenotypes: the microsatellite 
instability (MSI) and the chromosomal instability (CIN) phenotype [95]. CIN is responsible 
for approximately 85% of all sporadic colorectal cancers in addition to FAP tumors, and has 
been defined to have an accelerated rate of gains and losses of whole or large portions of 
chromosomes in the context of continuous growth [96], resulting in aneuploid tumors. More 
than 100 genes are expected to cause chromosomal instability when mutated, including genes 
that are involved in telomere metabolism, chromatid cohesion, spindle assembly and 
dynamics, cell-cycle regulation, DNA repair and checkpoint controls [97]. However, the 
actual mechanism(s) responsible for the genomic/chromosomal instability has only been 
identified in a small subset of tumors [98]. The CIN tumors are usually located in the left side 
of the colon, and the patients have poorer prognosis than do patients with MSI tumors [99]. 
The second group, those with MSI account for in approximately 15% of sporadic colorectal 
cancers, and additionally, tumors of the HNPCC spectrum follow this pathway. Tumors with 
the MSI phenotype is characterized by mutations or epigenetic changes in genes that maintain 
genetic stability, the mismatch repair genes [93], and is recognized by frameshift mutations in 
microsatellite repeats located throughout the genome. The MSI found in HNPCC is associated 
with defective DNA mismatch repair proteins caused by germline mutations in the one of the 
three main genes: MLH1, MSH2 and MSH6. In contrast to HNPCC, the cause of MSI in 
sporadic colorectal cancer is frequently biallelic or hemiallelic methylation of the promoter 
sequence of MLH1, thus silencing the gene and causing reduced or lost protein expression 
[100]. The tumors displaying MSI are usually found on the right side of the colon, and are 
most often diploid. 
 
Also a third phenotype, CpG island methylator phenotype (CIMP), has been suggested [101]. 




tumors display frequent methylation of several loci. These tumors show some overlap with 
the MSI phenotype and are associated with a proximal location within the colon. The CIMP 
negative tumors on the other hand, hardly show any cancer specific methylation. The CIMP 
model has been extensively discussed in the literature, since some studies support the original 
findings [102,103], whereas others do not [102,104]. 
 
Testicular germ cell tumors 
Ninety-eight percent of testicular cancers are of germ cell origin, and hence are called 
testicular germ cell tumors (TGCTs). These tumors are comprised of: teratomas and yolk sac 
tumors of newborn and infants, seminomatous and non-seminomatous tumors of adolescents 
and young adults, and spermatocytic seminomas of elderly men. The various groups of 
tumors originate from germ cells at different stages of development, and are clinically, 
epidemiologically and genetically distinct [105]. The entity of seminomas and non-
seminomas of young men is by far the most common form, and also the focus of this thesis. 
 
Epidemiology  
TGCTs account for 60% of all malignancies diagnosed in men between 20-40 years of age. 
The incidence has doubled the last 40 years, and an annual increase of 3-6% have been 
reported for Caucasian populations [88], however, the reason for this rapid increase is not 
known. The highest incidence is seen in people of Northern European decent, with the 
Scandinavian countries ranking high on the list. In Norway there is approximately 250 new 
cases each year4. In contrast, people from Africa or Asia have a low incidence of TGCTs, and 
since the differences persist after migration, it is suggested that the interaction between 
                                                 




genetic and environmental factors is important [106]. The cause of testicular cancer is still not 
elucidated, but there are several predisposing factors known. Chryptorchidism (undescendend 
testis), gonadal dysgenesis, a family history of TGCT, and various syndromes with abnormal 
testicular development, including Klinefelter’s syndrome (XXY), are associated with elevated 
risk of germ cell tumors. Patients with a history of TGCT also have increased risk of 
contralateral relapse [105]. Despite the increasing incidence, the mortality rate for TGCT 
patients has declined, the overall 5-year survival for all stages being approximately 80% 
[107]. This is due to major advances in treatment, including surgery, radiotherapy and 
chemotherapy. The overall goal for treatment is tumor-free survival for any TGCT patient, 
and this has already been reached for >99% of the patients with early-stage tumor, as well as 
for the majority of patients with advanced disease [107]. The high cure rate has brought 
attention also to the long-term effects of treatment, and data from these studies are now 
shaping treatment strategies that aim to keep clinical interventions at a minimum [106]. The 
main concerns are malignancies in other organs, cardiovascular disease and fertility, the latter 
being especially important because of the early on-set age of the disease. Overall, since TGCT 




TGCTs are classified into two subgroups: the seminomas and the non-seminomas, which are 
approximately equally common. These subgroups are both thought to develop through a non-
invasive stage termed intratubular germ-cell neoplasia (ITGCN), or carcinoma in situ, which 
is suggested to initiate during fetal life from a primordial germ cell (PGC) [108]. The 
seminomas are in many ways resembling the ITGCNs, whereas non-seminomas include 
various tumor subgroups. They develop through a pluripotent embryonal carcinoma stage, 




choriocarcinomas or into somatically differentiated teratomas. In many respects, this germ 





Figure 13: The association between A) embryogenesis and B) testicular cancer tumorigenesis. 
Abbreviations: ITGCN, intratubular germ-cell neoplasia. From Skotheim et al, ref. [109]. 
 
 
Genetic and epigenetic changes 
Genome amplification is an early event in the development of germ cell tumors and TGCTs 
are in general aneuploid. ITGCNs and seminomas typically have hypertriploid genomes 
[110], whereas the non-seminomas usually are hypotriploid [111] [112,113]. A complex 
pattern of chromosome gains and losses has been identified, both in the seminomas and the 




chromosomes 7, 8, 12 (see below) and X is found [88,113].  Karyotypic analyses have 
identified a specific marker, isochromosome 12p, consisting of two fused 12p-arms [114]. 
This chromosomal aberration have been found in virtually all testicular tumors, and identified 
in all histological subtypes, as well as in some ITGCNs [115], however the latter is debated. 
TGCTs without isochromosome 12p, still show amplifications of 12p sequences, indicating 
an early event of crucial importance for the development of cancer [88] Gene expression 
profiling has showed that various genes are overexpressed or altered in these tumors, 
including GRB7, JUP and FHIT [116,117] [118]. Only few mutated genes have been 
identified in TGCTs and then only at low frequencies. An activating mutation in codon 816 of 
KIT, which is a tyrosine kinase receptor, have been shown to be associated with development 
of bilateral TGCTs, and it is the first genetic event demonstrated to have a role in the 
initiation of testicular tumors [119]. The transcription factor POU5F1 (alias OCT3/4), which 
is usually involved in regulation of pluripotency and characteristic of primordial germ cells, is 
found in ITGCN, seminomas and embryonal carcinomas [120], thereby representing a new 
diagnostic marker for undifferentiated TGCT. Epigenetic changes have also been identified in 
germ cell tumors like a genome wide hypomethylation, consistent with what is observed in 
other cancer types, and a regional hypermethylation. In general, seminomas show scarcely 
CpG methylation whereas the non-seminomas show CpG island methylation levels similar to 




Malignant peripheral nerve sheath tumors  
Epidemiology 
Malignant peripheral nerve sheath tumors (MPNSTs) are highly invasive, soft tissue sarcomas 
that arise within the peripheral nerves and frequently metastasize. Half of all MPNSTs are 
sporadic cases whereas the rest arise in individuals with the autosomal, dominant genetic 
disorder neurofibromatosis 1 (NF1). MPNSTs occur in 2-5% of NF1 patients, compared to an 
incidence of 0.001% in the general population [122]. The MPNSTs are usually resistant to 
conventional radiation and chemotherapy, and their location around the nerves prevents 
complete surgical resection, thus the 5-year survival rate ranges from 34-52% [55]. 
 
Neurofibromatosis 1 
NF1, also known as von Recklinghausen disease, is caused by mutations in the NF1-gene, 
located on chromosome arm 17q. A wide variety of mutations have been found, but no 
frequently recurring mutation has yet been identified. The gene is large, spanning 350 kb 
genomic DNA, containing 60 exons, and it encodes the protein Neurofibromin [123]. Part of 
the protein shares sequence homology to the GTPase activator protein family that negatively 
interact with RAS oncogenes to regulate cell growth and differentiation, (See page 28). The 
GAP activity of Neurofibromin, in addition to NF1mutations in benign neurofibromas and 
malignant tumors associated with NF1, have led to the classification of NF1 as a tumor 
suppressor [124]. Individuals affected with NF1 harbor an increased risk of developing both 
benign and malignant tumors, supporting the classification of NF1 as a cancer predisposing 
syndrome. The prevalence of clinically diagnosed NF1 patients range from 1/2000 to 1/5000 
in various population-based studies [123].  
 




of Health (NIH) defined a set of diagnostic critera for NF1, where the patient ought to have 
two or more of the following features: neurofibromas, six or more café au lait spots, freckling 
of armpit or groin, optic glioma, Lisch nodules, distinctive bony lesions and a first degree 
relative with NF1 [125]. 
 
The hallmark of NF1, development of multiple neurofibromas, have two characteristic 
features: they invariably arise within peripheral nerves, and they are heterogeneous tumors 
that contain every cell type present in normal peripheral nerves, including Schwann-cells, 
perineural cells, fibroblasts and infiltrating mast cells. Dermal and plexiform are the two main 
types of neurofibromas in the setting of NF1. The first spontaneously cease growth and rarely 
progress to malignancy, whereas 5% of the latter undergo malignant transformation. There are 
indications suggesting that dermal neurofibromas might arise from a mature Schwann-cell 
lineage, whereas plexiform neurofibromas probably are derived from embryonic Schwann-
cell lineages (Figure 14) [55].  In patients harboring an inherited NF1-mutation, Schwann-






Figure 14: Development of Schwann cells and neurofibromas. MPNSTs usually develop from plexiform 




The progression to malignancy – Neurofibromas to MPNST 
The genetic changes underlying the malignant transformation of plexiform neurofibromas are 
not completely understood. However, there is an indication of a multistep process including 
several genetic, and possibly also epigenetic, alterations. Loss of Neurofibromin is believed to 
be the earliest event leading to tumor formation as patients inherit a mutated NF1-allele and 
loose the second copy in MPNST cells [127]. However, previous studies have demonstrated 
that loss of NF1-gene expression resulting in increased RAS activation alone is not sufficient 
for MPNST development [122]. Another early alteration in MPNST development is the 
expression of epidermal growth factor receptor (EGFR). Whereas EGFR is not expressed in 
normal human Schwann-cells, the protein is detected in primary MPNSTs, cell lines and 
subpopulations of neurofibroma Schwann cells [128]. MPNSTs exhibit complex karyotypes 
without a consistent cytogenetic pattern [129] [130] and comparative genomic hybridization 
(CGH) has been used to analyze gains and losses of DNA sequences and to map the copy 




MPNST are gains of 17q which might reflect amplification of Topoisomerase IIα (TOP2A) 
[131], and loss of 9p, 13q and 17p [130,132,133]. Based on CGH data and other studies 
reporting loss of heterozygosity, the tumor suppressor genes p16INK4A, RB1, and TP53 have 
been suggested targets for the deletions. TP53 is frequently mutated in various tumor types. 
Whereas expression in normal cells is usually low due to the short half-life of the protein, 
studies of sarcomas have detected expression of TP53 in MPNST and no or low levels of the 
protein in neurofibromas [134,135], which indicates an importance for TP53 in tumor 
progression. A few TP53 mutations have been reported for MPNSTs [136-138], but biallelic 
inactivation seems to be rare [139]. The CDKN2A locus encodes the protein products 
p16INK4A and p14ARF, both important in negative regulation of the cell cycle through their 
interaction with the RB1 and TP53 pathway, respectively [13]. Studies of p16INK4A have 
revealed gene alteration in 50-75% of the MPNSTs analyzed [140,141] However, alterations 
in neurofibromas are not reported, emphasizing the importance of disrupted p16INK4A in the 
progression of the MPNSTs. Data from our group, [142], implies that the complete absence of 
p16INK4A  is sufficient for activation of the cell cycle in most MPNSTs, consequently it is not 
necessary to alter other central components of the cycle to further stimulate tumor 
proliferation. In addition, genetic alterations of RB1 and amplification of CDK4 have been 
detected in MPNSTs that lack alterations of p16INK4A [143], indicating that the RB1-mediated 
G1/S-checkpoint pathway might be crucial. Furthermore, loss of expression of p27KIP1, 
another component of the RB1-pathway, has been identified in most MPNSTs (91%) 
compared to only 6% of the neurofibroma [135]. A recent global gene expression profile 
study found that among others, TWIST1 is over-expressed in MPNSTs. This gene, which 
inhibits expression of p14ARF thereby bypassing TP53 induced apoptosis, might turn out to be 
an attractive therapeutic target for novel MPNST treatment strategies. Stable suppression of 




expression in MPNST cells can inhibit chemotaxis, a key component of the metastatic 




Master keys in cancer 
Master keys in cancer biology can be defined at the level of single genes, gene families, 
signaling pathways, and cellular processes. Genes that are commonly altered across various 
cancer types, resulting in dysfunction of the encoded products, may be looked upon as master 
keys in tumor development. The tumor suppressor TP53 is an excellent example of such a 
master key, as it has an influence on several signaling pathways and cellular processes, 
comprising the downstream TP53 network. Mutations in TP53 are found in more than 50% of 
all solid tumors. Furthermore, by systematic mutational analysis of any gene family in any 
human cancer type, specific classes of proteins with particular importance in cancer may be 
identified. This is well exemplified by the “tyrosine kinome”, where a systematic approach 
showed that at least 30% of all colorectal cancers had one or more mutated tyrosine kinase 
[144]. In the normal cell, the members of the kinome and the phosphatome, kinases and 
phosphatases, respectively, have important functions by activating and deactivating proteins. 
A pathway can represent a master key if mutually exclusive mutations among its factors, 
resulting in a similar functional consequence, are frequently found. The commonly altered 
canonical WNT signaling illustrates this, often through mutated APC, but alternatively 
through epigenetic or genetic changes of other components [47,145,146]. Although the 
molecular biology of cancer is too complex to be understood by looking at single factors, the 
analysis and identification of single gene master keys may aid in unraveling the molecular 
understanding of the tangled networks in which they normally participate, and how alterations 
at this step influence cancer development and progression. 
 
 53 
Aims of the study 
 
In the present study we hypothesized that key factors upstream of central signaling pathways 
may be commonly altered in cancer. In the epithelial cancers of the large bowel, alterations 
have previously been described for the five genes analyzed, although not in the same clinical 
series, and only limited knowledge exists with regard to the involvement of these genes in two 
other cancer models, arising in the peripheral nerves and in the testis. Furthermore, 
information across the three diseases remains unknown. 
 
The aims of this study were two-fold: 
1. To identify the frequencies and type of alteration of genes known to be upstream 
components in cancer critical pathways, in tumors that arise from cells originating from 
distinct embryonal germ layers. This includes colorectal-, testicular-, and malignant 
peripheral nerve sheath tumors, from the endoderm, primordial germ cells, and 
neuroectoderm, respectively.  
 
2.  To find out if alterations in genes belonging to the same pathway are mutually exclusive 











From an unselected, prospective series collected from 7 hospitals in the South-East region of 
Norway during 1987-1989, 66 carcinomas from 65 individual were included in the present 
study [147]. The series are evaluated to contain a mean number of 84% neoplastic cells. Of 
the tumors, 36 were characterized as MSS and 30 as MSI. One of the tumors was from a 
patient with hereditary non-polyposis colorectal cancer (HNPCC), whereas the rest of the 
cases were sporadic. See Appendix IV for gender, age, localization and MSI status. 
 
Testicular cancer 
Primary tumor samples were obtained from 46 Norwegian patients diagnosed TGCT and 4 
diagnosed ITGCN. The frozen tumor sample from each patient was sliced and three sections 
were stained with hematoxylin and eosin in order to estimate the fraction of neoplastic cells 
versus normal cells. Across the sample set, an average of 75% neoplastic tissue was observed 
(range: 30 to 100%). All frozen tumor samples were classified according to WHO 
recommendations. Nineteen of the tumors were seminomas, and 27 were non-seminomas. See 
appendix IV for histopathological status. The non-seminoma group included 10 embryonal 
carcinomas, 8 teratomas, 6 yolk sac tumors, in addition to 3 tumors in which the exact 





Malignant peripheral nerve sheath tumors 
Thirty-two MPNSTs, including 12 from Swedish patients, 10 from Norwegian patients and 10 
from Dutch patients, were submitted to mutation and methylation analyses. Of the patients, 21 





DNA isolation  
DNA from fresh-frozen tumors taken from the colorectal carcinomas, TGCT and the MPNST 
patients had previously been isolated using a 340 A Nucleic Acid Extractor (Applied 
Biosystems). The standard phenol/chloroform extraction principle was applied [148], which 
presents DNA of high quality and yield. 
 
Mutation analysis 
PCR prior to DNA sequencing 
In 1971, Kleppe and co-workers initially presented a method named repair replication to 
replicate short synthetic DNA by the use of DNA polymerases [149]. However, Mullis has 
been acknowledged for inventing the technique of Polymerase Chain Reaction (PCR) in the 
1980s [150]. PCR uses the naturally occurring enzyme polymerase, to amplify a DNA 
fragment in a chain reaction. The reaction consists of three steps, denaturation, primer 
annealing, and elongation, that are repeated over and over, resulting in an exponentially 
accumulation of the target DNA. Prior to DNA sequencing, PCR products from the individual 
genes and exons were generated. A total of 25µl PCR-mix was prepared from: 2 ng template, 
1x PCR buffer (containing 1.5 mM MgCl2) (Qiagen, GmbH, Hilden, Germany), 0-0.5 µl 25 
mM MgCl2, 0.6 pmol of each primer (Medprobe AS, Oslo, Norway), 0.2 mM of each of the 
four dNTPs (Takara Bio Inc), and 0.03 U Hotstar Taq Polymerase (Qiagen). The total volume 




particles. For primer sequences see Appendix II. 
 
PTEN 
For mutation analysis of PTEN, we used primers designed by an in-house collaborative lab 
[151]. However, we optimized the reaction by using a multiplex PCR kit (Qiagen), which 
allowed the nine exons to be amplified simultaneously in one PCR (See fig 15). A total of 25 
µl PCR-mix was prepared, including 2 ng template, 1x Multiplex PCR Mastermix (containing 
buffer, 1.5 mM MgCl2, nucleotides, and enzyme), 0.048 pmol of each of the nine primer 
pairs, and adjusted the final volume with MQ-H2O. 
 
 
Figure 15: PCR products of the nine PTEN exons. The left panel is showing all exons simultaneously 
amplified by a multiplex PCR kit in six distinct samples. The right panel is showing the individual bands for 
each exon amplified in one sample, demonstrating that all exons are present, even though only six to eight bands 
are distinguishable in the left panel (white arrows). (It should be pointed out that the multiplex PCR reaction is 
not optimized for running single exons.) Abbreviations: M, marker (left: 100 base pair marker, right: φx marker); 




PIK3CA, KRAS and BRAF 
The primers for PIK3CA exon 20 and KRAS exon 2 and 3, were designed using the primer-
design program Oligo, whereas the primer pairs for BRAF and PIK3CA exon 9, were found in 
the literature [59] [152]. 
 
PCR programs 
A Robocycler Gradient 96 (Stratagene, La Jolla, CA, USA) and an Eppendorf Mastercycler 
Gradient (Eppendorf, Hamburg, Germany) machine were used to carry out the PCRs. All of 
the programs started with 15 minutes at 95°C to activate the enzyme, followed by 35 cycles of 
30-45 seconds of denaturation, 30-60 seconds at a specific annealing temperature, 30-60 
seconds of elongation at 72°C, and a final extension at 72°C for 8 minutes. (See table x, 
Appendix II, for the various conditions for each gene.) The PCR products were separated by 
electrophoresis at 200 V for approximately 20 minutes using either a 2 % agarosegel (BioRad 
Laboratories Inc., CA, USA) with ethidium bromide (Mercury Continental Lab Products Inc., 
CA, USA, Sigma Chemical Co., St.Louis, MO, USA) added, or a 7,5 % polyacrylamide gel 
stained with ethidium bromide for 2 minutes. A Gene Genius (Syngene, Cambridge, UK ) 
with UV-light was utilized to take photographs of the gels. 
 
PCR product purification 
A post-PCR purification step is required prior to the sequencing reaction, since leftover 
primers or free dNTPs may lead to background and noise in the sequencing electropherogram. 
Two different methods were used for purification, a column based approach utilizing the S-
300 HR MicroSpin columns (Amersham Bioscience, Buckinghamshire, UK) and an 
enzymatic purification using ExoSAP-IT (GE Healthcare, USB corporation, Ohio, USA). 
 




(pH 7.6). The resin was resuspended by vortexing, the cap loosened and the bottom closure 
was removed. The columns were placed in a 1.5 ml Eppendorf-tube for support, and pre-
spinned at 3000 rpm in an Eppendorf Centrifuge 5415 D (Eppendorf) for 1 minute. The 
columns were transferred to new Eppendorf-tubes, the caps were removed, and 20 µl PCR-
product was applied to the top centre of the resin, followed by centrifugation at 3000 rpm for 
two minutes. The purified samples were collected in the bottom of the Eppendorf-tubes. 
 
The ExoSAP-IT purification is a rapid and efficient protocol, which utilizes two enzymes, 
Exonuclease I and Shrimp Alkaline Phosphatase. One and a half µl ExoSAP-IT (Amersham 
Bioscience) was added directly to 10 µl PCR-product.  The mix was then incubated 15 
minutes at 37°C, followed by an inactivation step of 15 minutes at 80 °C on an Eppendorf 
Mastercycler Gradient PCR machine. 
 
See table 1, page 62, for the various applications on the different machines. 
 
Sequence reaction 
In 1969, Atkinson and co-workers showed that the inhibitory activity of dideoxythymidin 
(ddTTP) on DNA polymerase I depends on its incorporation into the growing oligonucleotide 
chain in the place of a thymidylic acid (dTTP). In contrast to the deoxyribonucleotide, which 
contains a hydroxyl group at the carbon in the 3rd position, the dideoxynucleotides contain an 
H atom, thus obstructing the chain from being extended further [153]. In the wake of that 
discovery, Gilbert, together with graduate student Maxam, and Sanger in 1977 independently 
developed new techniques for rapid DNA sequencing [154] [155]. The methods devised by 
Gilbert and Sanger laid the foundation for the techniques utilized today. So, in 1985, when 




enzymatic sequencing, which had become the laboratory standard [156]. In automating the 
process, Hood simultaneously modified both the chemistry and the process of collecting the 
data. 
 
The standard sequence reaction is similar to the PCR reaction for replicating DNA. The 
reaction mix included the purified PCR product as a template, 0.15 pmol of one of the primers 
(either the forward or the reverse), BigDye Terminator v1.1 Cycle Sequencing Kit (Applied 
Biosystems), BigDye Terminator v1.1 5x Sequencing Buffer (Applied Biosystems) and MQ-
H2O. The reaction was run in the presence of dNTPs and a small fraction of ddNTPs. The 
ddNTPs are chemically modified with fluorescent labels, which emit light at specific 
wavelengths when exposed to the light from a laser beam. This provides a way of visualizing 
the individual DNA bases. When a ddNTP is incorporated instead of a regular dNTP, the 
extension reaction stops because of the H-atom. This means that every strand is of various 
lengths, dependent on when the polymerase incorporated a ddNTP. Starting with denaturation 
at 96°C for two minutes, followed by 25 cycles of 15 seconds denaturation at 96°C, 5 seconds 
of annealing at 50°C and 4 minutes elongation at 60°C, the sequence reaction was carried out 
on a Robocycler Gradient 96 PCR machine. 
 
Sequence product purification  
After the sequencing reactions, and prior to separation on a DNA sequencer, the mixture of 
strands has to be purified. This was also done in two distinct ways, one method based on 
ethanol precipitation and one based on gel filtration. 
 
Ethanol precipitation 
To precipitate the sequence product, 2 µl 3 M sodium acetate CH3COONa (pH 4.6) and 50 µl 




The samples were spun at full speed (2250g) for 45 minutes on an Eppendorf Centrifuge 5804 
(Eppendorf). The sample-tubes were opened, turned up side down on a paper and spun for 1 
minute at 700g to remove the supernatant. Hundred and fifty µl 70% ethanol was added, and 
the samples were spun 25 minutes at full speed, prior to a repeat of turning the sample-tubes 
up side down on a paper and spinning for 1 minute at 700g.  Finally, 5 µl loading buffer 
consisting of 4 µl deionised formamide CH3NO (Merck, Darmstadt, Germany) and 1 µl Blue 
Dextran/EDTA (Applied Biosystems, Foster City, CA, USA) was added to the samples 
followed by denaturation of the products for 3 minutes at 95°C. 
 
Gel filtration 
Using the gel filtration method, dry Sephadex G-50 Superfine (Amersham Bioscience) was 
loaded on to a 96-well Multiscreen HV plate (Millipore), using a Column Loader 45 µl plate 
(Millipore). Three hundred µl MQ-H2O was added to each well and the Multiscreen plate was 
incubated at room temperature for 2 hours for swelling of the resin. The Sephadex-powder 
and water makes a gel-column that is able to separate molecules according to size. Small 
molecules, like unincorporated dye terminators and excess primers, will diffuse into the pores, 
and their passage through the column is delayed. Molecules of larger size, like the sequence 
product, will pass directly trough the column. After swelling, the Multiscreen Plate was 
placed on top of an empty, old 96-well Optical Reaction Plate (Applied Biosystems), and 
centrifuged for 5 minutes at 910 g to pack the columns. To pre-rinse the columns, 150 µl MQ-
H2O was added to each well, prior to another round of centrifugation for 5 minutes at 910 g. 
Ten µl MQ-H2O and 10 µl sequence reaction product was loaded on to each column, followed 
by centrifugation for 6 minutes at 910 g. The samples were collected in the wells of a new 96-
well Optical Reaction Plate and the plate was immediately covered with a 3100 Genetic 




to sequencing, since the polymer contains urea. 
 
DNA sequencing 
After the sequence reaction and purification, the various fluorescent labeled fragments, all of 
different length, have to be separated. This was done either on a polyacrylamide gel using an 
ABI PRISM 377 machine or in a polymer-filled capillary array utilizing an ABI PRISM 3730. 
Both machines are capable of separating molecules by gel electrophoresis in which the length 
differ by no more than one base. At the bottom of the gel or the capillary array, the fragments 
are passing a laser beam that excites the fluorescent molecule, which in turn, emits light. The 
light is collected simultaneously and focused by lenses into a spectrograph. Based on the 
wavelength, the spectrograph separates the light across a charge coupled device (CCD) 
camera. Since each base has a distinct fluorochrome, the data collection software can read and 
interpret the fluorescence data and display them as electropherograms. 
 
The ABI PRISM 377 DNA Sequencer is the most time and work consuming machine, mainly 
because a 4.5% polyacrylamide gel has to be prepared. Fifty ml solution was made of 18.0 g 
Urea (BioRad), 5.63 ml 40% Acrylamide/Bis solution 29:1 (BioRad), 20 ml MQ-H2O, and 
0.5 g Amberlite MB-150 (Sigma). The mix was filtered by utilizing a Steritop Filter 
(Millipore) and vacuum, which also removes gas and prevents bubble formation in the gel. 
Ten ml 5x TBE-buffer (Trisma Base, Boric acid, 0.5 EDTA, MQ-H2O) was added, and the 
volume adjusted by MQ-H2O. To polymerize the gel, 125 µl 20% ammonium persulfate 
(APS) (BioRad) and 30 µl TEMED (BioRad) were added, where-upon the gel-solution was 
injected between clean 36 cm glass plates, separated by two 0.2 mm gel spacers. On the top, a 
36 lane, 0.2 mm Sharks tooth comb was inserted. The gel polymerized in room temperature 




were run at 51°C for 6.5-7 hours. 
 
The ABI PRISM 3730 DNA Sequencer is fully automatic and hence very effective in contrast 
to the 377. The 96-well Optical Reaction Plate containing the samples, was put in a 96-well 
Plate Base, and placed in the machine. Instead of a polyacrylamide gel, the capillary array is 
filled with POP7 polymer (Applied Biosystems). The samples were run at 60°C for 2 hours. 
 
Approximately 80% of the BRAF mutations analyses were run using the 377 DNA sequencer, 
whereas the rest of the analyses, including the other 3 genes, were run on the 3730 DNA 
sequencer. 
 
All the samples were analyzed using the DNA Sequencing Analysis software (Applied 
Biosystems.) 
 
Table 1: The various purification methods applied prior to DNA sequencing. 
 
The electropherograms have been manually read, and all positive findings have been verified 
by a second independent run, as well as by another member of our group. 
ABI PRISM DNA SEQUENCER 377 3730
Purification of PCR product: S-300 HR Microspin Columns ExoSapIT
Sequence reaction (µl):
MQ-H2O 8.50 6.25
Big Dye buffer 0.00 1.50
Big Dye Mix 6.00 1.00
Primer 0.50 0.25
PCR-product 5.00 1.00
Total (µl): 20.00 10.0
Purification of





The principle of Methylation-Specific PCR (MSP) 
A bisulphite treatment reaction for deamination of cytosine derivatives was initially described 
in 1970 by Shapiro et al [157]. However, Frommer and Clark were the first to present sodium 
bisulphite (NaHSO3) treatment as a way to distinguish between 5-methylcytosines and 
cytosines in the 1990s. It is a reaction where unmethylated cytosines are deaminated and 
converted to uracils, which then replicate as thymines during PCR, while the methylated 
cytosines remains unchanged (figure 16) [158,159]. 
 
 
Figure 16: The stepwise conversion of unmethylated cytosine to uracil by sodium bisulphite treatment. 




In 1996, Herman and co-workers introduced MSP as a method to analyze the DNA 
methylation status of CpG sites. The technique consists of two parts; 1) the sodium bisulphite 
treatment of the DNA, and 2) revealing of the differences in the sequences induced by the 
bisulphate using PCR. After the treatment, the DNA strands will no longer be complementary, 
thereby requiring primer sets specific for unmethylated and methylated DNA [160]. MSP is 
the most widely used methylation assay today, since it is simple, quick, cost effective, and at 
the same time sensitive, as it can detect one methylated allele in a pool of 1000 unmethylated 
alleles [28,160]. In the present thesis we used MSP to assess methylation status of RASSF1A. 
 
Bisulphite treatment of DNA 
One point three μg DNA was diluted in a total volume of 50 μl in eppendorf-tubes by adding 
MQ-H2O. Five point seven μl 3M sodium hydroxide (NaOH) (Merck) was added to each 
sample, prior to incubation for 10-15 minutes at 37°C to denature the DNA. This is an 
important step, as only cytosines located in single strands are available for modification [30]. 
Next, 33 μl 20mM hydroquinone (Sigma-Aldrich Inc., St. Louis, MO, USA) was added. This 
is an anti-oxidant and prevents oxidative damage to the DNA caused by the bisulphite 
treatment. Finally, 530 μl 4.3M Sodium Bisulphite (pH 5.00) (Sigma-Aldrich) was added to 
each sample prior to incubation for 16-17 hours (over night) at 50°C. The next day, 1 ml resin 
from DNA Wizard clean-up kit (Promega Ltd., Southampton, UK), which binds the DNA 
prior to the clean-up procedure, was added. After mixing, the samples were loaded onto 
filtered columns mounted on a vacuum manifold. The vacuum causes the liquid to pass down 
through the filters, and the columns were re-filled with 80% isopropanol (Merck, Darmstadt, 
Germany) to rinse the modified DNA. When the isopropanol had passed through the filters, 
they were placed in the old eppendorf-tubes and centrifuged for 2 minutes at 12700 rpm to 




DNA was eluted by adding 50 μl MQ-H2O and spun for 1 minute at 12700 rpm. This step was 
repeated once, thus the DNA was dissolved in 100 μl. In order to complete the transformation 
from C to U, 11.4 μl 3M NaOH was added to each tube, prior to incubation for 15 minutes at 
37°C. To visualize the DNA pellet during precipitation, 2 μl glycogen (5 mg/ml) (Ambion 
Ltd., Huntingdon, Cambridgeshire, UK) was mixed in. Nine hundred μl cold 100% ethanol 
and 42 μl 7.5 M ammonium acetate (AcNH4) (Sigma-Aldrich) were added to precipitate the 
DNA at -80°C over night. In a pre-cooled centrifuge (Eppendorf) the samples were spun for 
30 minutes at 13000 rpm in 4 °C. The supernatant was removed, 1 ml cold 70% ethanol added 
to the pellet and centrifuged for 15-30 minutes at 13000 rpm in 4 °C.   
In order to remove all the ethanol, the supernatant was again discarded, the lids were opened 
and the samples heated to 50 °C for less than 1 minute to let the rest of the ethanol evaporate. 
Finally, the bisulphite treated DNA was dissolved in 30 μl MQ-H2O. 
 
Methylation specific PCR (MSP) of RASSF1A 
The PCR mix consisted of 2 ng bisulphite treated DNA, 1x Qiagen PCR buffer (containing 
1.5 mM MgCl2), 1.6 pmol of each of the primers (Medprobe), 0.2 mM of each of the four 
dNTPs (Takara Bio Inc., Shiga, Japan), and 0.04 U Hotstar Taq Polymerase (Qiagen). The 
total volume was adjusted to 25 µl by adding MQ-H2O. The primers used for the RASSF1A 
MSP were designed by Koul and co-workers [161]. A Robocycler Gradient 96 (Stratagene) 
was used to carry out the MSP, starting with 15 minutes at 95°C to activate the enzyme, 
followed by 35 cycles of 30 seconds of denaturation at 95°C, 30 seconds annealing at 62°C, 
30 seconds of elongation at 72°C, and a final extension at 72°C for 7 minutes. (See also 
Appendix II.) The PCR products were separated by electrophoresis at 200 V for 
approximately 30-40 minutes using a 2 % agarosegel (BioRad) with ethidium bromide 




photographs of the gels. Bisulphite converted DNA from normal blood was used as a positive 
control for the unmethylated MSP reaction, whereas human placenta DNA treated in vitro 
with SssI methyltransferase (New England Biolabs Inc., Beverly, MA, USA) was used as a 
positive control for the methylated templates. This sample should be methylated in all CpG-
sites. The positive RASSF1A samples were visually scored relative to the intensity of the 
positive control as either weakly methylated (including less intense samples than the positive 
control) or heavily methylated (including samples with equal or higher intensities than the 
positive control.) Samples displaying a band from the unmethylated reaction but not 
displaying any band from the methylated reaction were scored as unmethylated. For this 
thesis, only those samples scored as heavily methylated were classified as methylated, 
whereas the samples scored as weakly methylated were classified as unmethylated. This 
conservative way of classifying methylated samples limits the number of false positives. The 
author and another group member, Post. Doc. Guro E. Lind, have independently performed all 
visual scorings, and all results were verified by a second round of analysis. The methylation 
analyses of testicular germ cell cancers were performed by Guro E. Lind. 
 
Statistics 
General references: Altman, 1999 [162] and More & McCabe, 2002 [163]. 
The Chi squared (χ2) test 
The Chi squared (χ2) statistic is a measure of how much the observed outcomes diverge from 
the expected outcome given that the H0-hypthesis (no association between the variables) is 
true. If the expected outcome and the observed outcome are very diverse, a large value of χ2 
will result. The further away the observed outcomes are from the expected, the less likely it is 




The formula for the test statistic is: 
χ2 = Σ 
E
EO 2)( − , where O denotes the observed frequency and E the expected frequency. The 
degree of freedom in Chi squared (χ2) tests is: df = (r – 1) (k – 1), where r denote the number 
of rows, and k denotes the number of columns. 
 
The Fisher’s exact test 
An alternative approach for tables with small expected frequencies is the Fisher’s exact test, 
which is based on the same principle as the Chi squared test. It can only be applied to 2 x 2 
tables, but is preferred over the Chi squared test as it is more accurate. 
 
All contingency 2x2 tables in the present thesis were analyzed using Fisher’s exact test, where 
the degree of freedom is 1. Three x 2 tables were analyzed by the Chi squared (χ2) test. All P 
values are derived from two tailed statistical tests using the SPSS 11.5 software, and values 




Mutation and methylation frequencies of 5 cancer relevant genes 
Hundred and forty-eight samples from three cancer types were analyzed for mutations in 
KRAS, BRAF, PIK3CA, and PTEN, and simultaneously for promoter methylation of 
RASSF1A. The overall alteration-frequencies for each gene in colorectal carcinomas, TGCTs 
and MPNSTs are summarized in table 2. The type of mutation and subsequent amino acid 
substitution are shown for the individual genes per sample in, appendix III. Figure 17 and 18 
illustrates the mutation spectra, whereas figure 19 shows promoter methylation of RASSF1A. 
 
Table 2: Mutation and methylation frequencies in colorectal carcinomas, testicular cancer and malignant 
peripheral nerve sheath tumors. 
 
RASSF1A was analyzed for promoter methylation, whereas the rest of the genes were analyzed for mutations. 
Abbreviations: CRC, colorectal carcinomas; TGCT, testicular germ cell tumor; MPNST, malignant peripheral 
nerve sheath tumor. 
Gene CRC TGCT MPNST
KRAS 26/66  (40%) 2/47 (4%) 0/32 (0%)
BRAF 14/65 (22%) 1/48 (2%) 1/32 (3%)
RASSF1A 18/60 (30%) 8/49 (16%) 14/30 (47%)
PIK3CA 15/64 (23%) 0/46 (0%) 1/31 (3%)






Figure 17: Mutation spectra and electropherograms for KRAS and BRAF across tumor types. The figure 
illustrates the genetic position and type of mutations detected in colorectal carcinomas, testicular germ cell 
tumors and malignant peripheral nerve sheath tumors for a) KRAS and b) BRAF. 
Abbreviations: aa, amino acid; bp, base pairs; A, Alanine; C, Cysteine; D, Aspartic acid; E, Glutamic acid; G, 








Figure 18: Mutation spectra and electropherogram for PIK3CA and PTEN across tumor types. The 
figure illustrates the genetic position and type of mutations detected in colorectal carcinomas, testicular germ cell 
tumors and malignant peripheral nerve sheath tumors for a) PIK3CA, and b) PTEN.  
Abbreviations: aa, amino acid; bp, base pairs; A, Alanine; E, Glutamic acid; G, glycine; H, Histidine; K, Lysine; 






Figure 19: Promoter hypermethylation of RASSF1A in malignant peripheral nerve sheath tumors. The 
methylation was evaluated by methylation-specific PCR (MSP). A visible product in lanes termed U, indicates 
the presence of unmethylated alleles, whereas a product in lanes termed M, indicates the presence of methylated 
alleles. Abbreviations: NB, normal blood (positive control for unmethylated samples); MP, methylated placenta 
(positive control for methylated samples); M, marker (100 base pair marker); Neg, negative control (containing 
water as template); U, lane for unmethylated MSP product; M, lane for methylated MSP product. 
 
Colorectal carcinomas 
In total, 80% of all the colorectal tumors, both MSI and MSS, were altered in one or more of 
the genes analyzed, and the observed changes were evenly distributed among the genes. The 
detailed results of the mutation and methylation analyses in colorectal tumors, in addition to 
comparisons with other known tumor genetics are summarized in table 3, whereas 





Table 3: Mutation and methylation of the individual genes, compared with the other genes analyzed, as 
well as to mutation status of TP53 and APC. 
 
Comparisons of different groups were tested with Fisher’s exact test or Chi squared test. Abbreviations: Wt, wild 
type; Mut, mutation; U, unmethylated; M, methylated; NS, not significant. 
 
 
Inverse associations were found between mutations in KRAS versus BRAF, and also for KRAS 
versus PTEN, (P = <0.001 and P = 0.002, respectively). Additionally, mutations in BRAF and 
PTEN were associated (P = 0.012). Mutations in TP53 and APC, previously analyzed in the 
same sample series, were compared to the results of the genes investigated here. Twenty-six 
tumors had KRAS mutations and eighteen of these harbored wild type APC (P = 0.045). 
Methylation of RASSF1A was frequently found together with wild type APC (P = 0.089), 
whereas mutations in BRAF displayed a trend towards the opposite (P = 0.069). Tumors with 
Wt Mut Wt Mut U M Wt Mut Wt Mut
KRAS
Wt - - 26 14 25 11 32 7 26 25
Mut - - 25 0 17 7 17 8 12 0
P value
BRAF
Wt 26 25 - - 31 15 38 12 44 6
Mut 14 0 - - 11 3 11 3 7 6
P value
RASSF1A
Unmethylated 25 17 31 11 - - 32 10 34 7
Methylated 11 7 15 3 - - 13 5 13 5
P value
PIK3CA
Wt 32 17 38 11 32 13 - - 39 9
Mut 7 8 12 3 10 5 - - 12 3
P value
PTEN
Wt 26 12 44 7 34 13 39 12 - -
Mut 25 0 6 6 7 5 9 3 - -
P value
TP53 
Wt 18 13 24 6 19 9 23 7 23 7
Mut 11 7 17 1 10 5 14 3 17 0
P value
APC
Wt 17 18 30 4 19 13 25 9 30 4
Mut 23 8 21 10 23 5 24 6 21 8
P value
0.039
0.045 0.069 0.089 NS NS


























mutated PTEN were typically found in those with wild type status of TP53 (P = 0.039). 
 
Table 4: Mutations in PIK3CA compared with mutations in KRAS or BRAF in the same tumor. 
Abbreviations; wt, wild type; mut, mutation 
 
No significant association was found between mutations in PIK3CA and mutations in either 
KRAS or BRAF (table 4). 
 
Table 5: Mutation and methylation frequencies of the analyzed genes, compared with the patients’ 
clinicopathological features. 
Wt Mut Wt Mut U M Wt Mut Wt Mut Wt Mut
Individuals
No 40/66 26/66 51/65 14/65 42/60 18/60 49/64 15/64 51/63 12/63 10/63 53/63
Sex
Male 19 15 31 3 22 8 25 8 29 4 8 24
Female 21 11 20 11 20 10 24 7 22 8 2 29
P value
Age (years)
<68 18 8 21 5 17 7 22 4 23 3 5 19
≥68 22 18 30 9 25 11 27 11 28 9 5 34
P value
Site
Right side 17 7 15 9 20 3 20 4 14 9 3 20
Left side 14 10 21 2 13 9 15 8 21 2 5 19
Rectum 9 9 15 3 9 6 14 3 16 1 2 14
P value
MSI status
MSI 22 8 19 11 22 7 24 6 20 9 4 25
MSS 18 18 32 3 20 11 25 9 31 3 6 28
P value
Ploidy status
Diploid 28 14 31 11 27 12 32 10 30 11 7 33
Aneuploid 12 12 20 3 15 6 17 5 21 1 3 20
P value
Histological grade
Poorly differentiated 11 4 9 5 10 3 9 5 10 4 1 13
Moderately differentiated 28 19 38 9 29 14 38 8 37 8 8 37





NS 0.014 NS NS
RASSF1A PIK3CA
NS NS NS NS
0.05 NS



















Comparisons of different groups were tested with Fisher’s exact test or Chi squared test. Abbreviations: MSI, 
microsatellite instability; MSS, microsatellite stable; Wt, wild type; Mut, mutation; U, unmethylated; M, 
methylated; NS, not significant. The column termed TOTAL is the overall status of each tumor: the wild type 




Mutations in BRAF and PTEN were more common in MSI tumors (11/30, P = 0.008 and 
9/29, P = 0.05, respectively) as well as in tumors with a right-sided location in the colon 
(9/24, P = 0.047 and 9/23, P = 0.004, respectively). Additionally, PTEN mutations were 
typically found in tumors with diploid genomes. We saw a tendency of more mutations in 
some genes in females than in males, but this was only statistically significant for BRAF (P = 
0.014). Moreover, methylation of RASSF1A was more frequent in tumors of the left side of 
the colon and the rectum, but this observation was not statistically significant (P = 0.078).  
There were no statistical significant associations between changes in any of the genes and age 




Testicular germ cell tumors 
In total, 22% of all TGCT samples were altered in one or more of the genes analyzed. In fact, 
all changes were seen in RTK signaling through alterations of KRAS, BRAF, and RASSF1A 
(See Appendix III for details). 
 
Mutations in KRAS (n=2), BRAF (n=1), and PTEN (n=1), were found in four individual 
tumors, all in the seminomatous subgroup of TGCTs (See table 6). In contrast, all cases with 
hypermethylation of the RASSF1A promoter were non-seminomas (table 6 and 7). 
 
Table 6: Mutation and methylation frequencies of individual genes in the histological subtypes of TGCT. 
 
RASSF1A was analyzed for promoter methylation, whereas the rest of the genes were analyzed for mutations. 
Abbreviations: TGCT, testicular germ cell tumors; ITGCN, intratubular germ-cell neoplasia  
 
 
Table 7: Distribution of methylation in the none-seminomatous sub-group of TGCTs. 
 
 
A gene methylation profiling study of TGCTs was performed in parallel to this study [164]. 









KRAS 2/16 0/27 0/4
BRAF 1/17 0/27 0/4
RASSF1A 0/18 8/27 0/4
PIK3CA 0/15 0/27 0/4





RASSF1A as one of the most frequently methylated genes among the non-seminomatous 






















































Figure 20: Methylation percentages of target genes in non-seminomatous testicular germ cell tumors 





Malignant peripheral nerve sheath tumors 
In total, 50% of the MPNSTs were altered, mainly through promoter methylation of 
RASSF1A. Mutation and methylation frequencies for the individual genes in MPNSTs are 
summarized in table 8. RASSF1A was found hypermethylated in 14/30 cases (~ 47%), and this 
type of change seemed to be more common in cases with the hereditary disease NF1 than 
among the sporadic cases, although not statistically significant. On the other hand, BRAF and 
PIK3CA were mutated in only one tumor each and no mutations were seen in KRAS or PTEN 
in MPNSTs. 
 
Table 8: Mutation and methylation frequencies of individual genes in malignant peripheral nerve sheath 
tumors taken from patients with and without the disease Neurofibromatosis, who are carriers of germ line 
NF1 mutations. 
 
RASSF1A was analyzed for promoter methylation, whereas the rest of the genes were analyzed for mutations. 
Abbreviations: MPNST, malignant peripheral nerve sheath tumors. 
 
No associations were found among the changes in the MPNSTs and NF1-status or gender. 
Gene











The MPNST are typically genetic complex, but show a wide range of complexity. This is 
illustrated in figure 21, summarizing the genomic changes in 30 MPNSTs as assessed by 
chromosomal CGH in our laboratory (not part of the present study, data unpublished). The 
methylation of RASSF1A is evenly distributed among the samples, and thereby seemingly 
independent of the genetic complexity, which is also shown in figure 21. 
 
Figure 21: The genetic complexity of the MPNST samples. The changes include gain or loss from the whole 
or part of a chromosome arm. The numbers on top of the columns show the number of tumors with RASSF1A 





DNA sequencing is often considered the “gold standard” when it comes to mutational 
analysis, as the final outcome pinpoints the exact alteration of the DNA sequence. From this 
information one can identify the respective codon(s) affected and the amino acid alteration(s), 
and sometimes deduce the biological consequence at the protein level. However, it should be 
noted that direct sequencing of genomic DNA might not detect large deletions or inversions. 
 
The advantage of using direct sequencing is the requirement of only small amounts of 
material and the immediate identification of potential mutations. The overall mutation 
detection level can further be improved by including a highly sensitive prescreening step. A 
wide variety of such methods exist, including temporal temperature gradient gel 
electrophoresis (TTGE), single strand conformational polymorphisms (SSCP), and denaturing 
high performance liquid chromatography (DHPLC), however, most of these prescreening 
methods are labor-intensive and do not identify the exact alteration (for review [165,166]), 
and thereby one are in need for DNA sequencing to detect the exact base positions of the 
aberrations initially detected by the other methods. 
 
Two models of DNA sequencers were utilized to screen BRAF for mutations. The 377 DNA 
sequencer has a mutation detection level of approximately 20%, in contrast to the 3730 DNA 
sequencer, which has a sensitivity of approximately 10%. Some mutations might therefore 




will probably be of little significance for the tumor biology, as the tumor cells still will harbor 
sufficient amounts of wild type BRAF. Since all samples included in the present thesis contain 
a high percentage of tumor cells, a potentially undetected mutation can only be present in a 
few clones, and hence not contribute much to the overall phenotype. Heterozygous mutations, 
which are estimated to be present in approximately 30- 50% of the sample cells, will easily be 
detected by both sequencers. 
 
Most analyses were performed using the AB 3730 DNA sequencer. This 48 capillary 
instrument has high capacity and can analyze 96 samples in two hours. However, the most 
time consuming part is the correct reading of the sequences. A software program from 
Applied Biosystems is designed to detect the mutations, however this has not yet been tested 
adequately. The program does not seem to detect the smallest mutations, and therefore all 
sequences were read manually. For the four genes, a total of 15 fragments x 148 samples were 
sequenced both ways creating 4440 electropherograms to be manually read. By this approach 
only small discrepancies were recorded between the two group members reading. 
 
In the present thesis, we have performed sequencing of hotspots and of whole coding regions, 
chosen according to the existing knowledge about the mutational spectra of the genes in 
question. Hot-spots for mutation have been reported for selected exons of KRAS, BRAF, and 
PIK3CA, whereas no hot-spot mutations have been reported for PTEN [53,59,152]. The 
individual mutation spectra found in this study (figures 17 and 18) are in accordance with the 
original findings for the respective genes.  
 
Regarding the DNA methylation analysis, bisulphite sequencing is considered to be the “gold 




cancer cell lines, direct bisulphite sequencing provides results of sufficient quality. The 
amplified bisulphite PCR product from primary tumors, on the other hand, should be cloned 
into plasmid vectors, and 10-12 clones from each sample should subsequently be sequenced, 
as the individual clones might contain different degree of methylation. This is both laborious 
and time consuming. In contrast, the MSP method is quick and reliable and is now the most 
widely used technique for studying DNA methylation in large clinical series. The specificity 
of this assay relies on the match or mismatch of the primer sequence to bisulphite treated 
DNA and the choice of primers can therefore greatly influence the results. Here, we have used 
previously published MSP primers. The products obtained, indicating methylated or 
unmethylated sequences, have shown good associations to lack of/reduced or presence of 
gene product, respectively [161]. 
 
Gene mutations 
In colorectal carcinomas, mutations in APC, KRAS, and TP53 are common [46]. Many other 
genes have also been found to harbor point mutations in colorectal cancer, although not in 
such high frequencies [46]. Due to development of high throughput methods the last years, 
mutation analyses of gene families have also been performed, such as the kinome and 
phosphatome [144,167]. In addition to the actual mutations, the order of events is also 
important for the development of malignancies. All three cancer types investigated here have 
identifiable precursor lesions, providing the means to study the tumor progression. Colorectal 
cancer is a particularly suitable model for this, as pre-invasive lesions at various stages, as 
well as malignant and metastatic tumors easily can be isolated from the patient. In this 
developmental cancer model, some of the mutations preferentially arise early, including APC 




are frequent early events in colorectal cancer, it is not enough for a malignant transformation, 
underlined by the high rate of such mutations in benign adenomas. This is also the case for 
MPNSTs, as NF1-mutations are also seen in premalignant stages, as well as in the germline of 
patients with the hereditary disorder neurofibromatosis. 
 
In sporadic colorectal cancer, the KRAS-BRAF-MAPK and KRAS-PI3K-AKT pathways are 
frequently altered, and up to 75% of these carcinomas have activating point mutations in 
either KRAS, BRAF, or PIK3CA [168], a somewhat higher percentage than we have found 
(66%). However, the KRAS mutations presented here are found within the previously 
published range of 31-50% in colorectal cancer [53,168-170], showing that our results are in 
accordance with previous findings. It should further be noted that we selected our series to 
contain a similar number of MSI and MSS tumors, which do not reflect the distribution 
among an unselected clinical series. About one third of right-sided colorectal carcinomas 
show MSI, encompassing most of the tumors with this phenotype. 
 
Davies and co-workers showed that BRAF is mutated in a wide range of cancers, including 
colorectal cancer, with a trend towards cancer types known to harbor KRAS mutations [59]. 
Additionally, it has been shown that BRAF mutations are associated with distinct clinical, 
pathological, and molecular features, such as location in the right side of the colon, poor 
histological grade, frequent MLH1 promoter methylation, and MSI [60], which are in 
accordance with our results. The mutation frequency is usually within the range of 10-15% 
[59,168,171], however since our series is enriched in tumors showing a microsatellite 
unstable phenotype,  the resulting frequency (22%) is somewhat higher than what would be 
expected in an unselected series. This is also the case for PIK3CA and PTEN. Our data are in 




to 32.3% not stratified for MSI [71,77]. Mice with a homozygous deficiency of the p110alpha 
subunit, encoded by PIK3CA, were recently shown to be growth-retarded and die during 
embryogenesis, underlining the critical role for p110 in growth factor and metabolic signaling 
[172]. 
 
 PTEN is also a good candidate for involvement in the development and/or progression of 
sporadic cancer, even though mutations in this gene are relatively infrequent in colorectal 
carcinomas [173,174] when compared with tumors of the brain and the prostate [80,81]. The 
functional importance of PTEN is so severe that mutations may in itself provide the tumor 
cells with a selective advantage, so that only limited numbers of other gene defects are 
necessary. Indeed, in a study of 8 genes known to affect the WNT signaling, mutation in 
PTEN was the only example of a sole mutation among the investigated genes in single tumors 
[47]. Only few distinct point mutations have been reported in colorectal cancer, mainly in the 
two (A)6 repeats in exon 7 and 8 [47,173]. Here, we have identified several additional 
mutations, located in all but one exon (exon 9;figure 18), which to our knowledge have not 
been reported for this cancer type, despite of several previous studies of all the exons 
[174,175]. Hot spots are usually localized in regions that are of functional importance to the 
gene. The functional domains of PTEN are spanning most of the coding region (see figure 
18). This is consistent with the fact that the mutations were found evenly distributed 
throughout the domains instead of appearing in hot spots. This implies that the alterations 
might have the same functional effect regardless of the affected site. Furthermore, numerous 
tumors are showing more than one hit, possibly leading to biallelic inactivation, although no 
consistent pattern can be found. Also deletion of PTEN and/or loss of expression have been 
found in various cancer types, but does not seem to be prevalent in colorectal cancer [79]. 




be the operative event, and indeed, frequent inactivation of PTEN in various tumor types, 
including colorectal carcinomas [176], have been reported. However, the majority of the 
primer sets used are mistakenly designed for the frequently methylated pseudogene of PTEN 
showing a 98% homology with the protein encoding gene [177]. Unpublished data from our 
group show that PTEN is not subjected to promoter hypermethylation in colorectal 
carcinomas nor in colon cancer cell lines (Ahlquist et al, unpublished). 
 
In TGCT, the general prevalence of point mutations is low, in contrast to a high frequency of 
copy number changes. This is exemplified by TP53, which is frequently mutated in various 
cancer types, but not in TGCTs [178,179]. Previous work has documented activating 
mutations in the KIT receptor tyrosine kinase, although at low frequencies [119], with the 
exception of bilateral tumors. Some years ago it was showed that the protein kinase STK11 
(LKB1) was mutated in a low frequency in TGCT [180]. In a recent large study, the potential 
role of mutated protein kinases in the development of TGCT were examined by analyzing all 
the 518 genes of the annotated protein kinase family, however, only a single point mutation in 
the STK10 gene was found [181]. This was in contrast to the results from a similar study of 
colorectal cancer, where 10% of the analyzed genes were changed, affecting 31% of the cases 
investigated [144]. Mutations leading to activated RAS proteins of both KRAS and its 
homologue NRAS, have been detected in TGCT, although at various frequencies. More than a 
decade ago our group initially showed that KRAS could be mutated in TGCT [54], and in a 
review of the literature from 1995, the overall frequency of KRAS mutations was determined 
to 11%, with a higher incidence in seminomas than non-seminomas [182]. Our 4% KRAS 
mutations are within this previously published range [54,182]. Expression levels of KRAS 
have also been reported to be slightly increased in wild type TGCT [117], thus, it has been 




expression of up-stream regulators [183]. Regarding BRAF mutations in TGCT, there are only 
a few cases reported, which was published after the initiation of the present study. McIntyre 
and co-workers investigated 65 primary TGCTs and 4 TGCT cell lines, and found none [184]. 
Sommerer and co-workers investigated 62 TGCTs and identified 3 activating mutations in 
non-seminomas, none in seminomas [185]. In accordance to this, we have only found one 
BRAF mutations, however, it was found in a seminoma rather than a non-seminoma. 
Summarized, we can now conclude that BRAF mutations are rare events in TGCTs. Although 
of importance to single tumors, these aberrations are not characteristic to the pathogenesis of 
TGCTs. 
 
The PI3K signaling pathway is suggested to be involved in both neovascularization and cord 
formation during testis morphogenesis. However, to our knowledge, no reports regarding 
neither mutations nor expression levels of the PI3K-encoding gene, PIK3CA, have so far been 
presented in human TGCTs. Additionally, since we could not identify any mutations in the 
gene, it might not be important in the development of this cancer type. On the other hand, 
inactivation of PTEN, which negatively regulates cell growth, migration, and survival via the 
PI3K-AKT signaling pathway, leads to development of TGCT in heterozygous mice 
[186,187]. Further it is also is shown that PTEN marks the transition from intratubular germ 
cell neoplasias (ITGCN) to invasive germ cell tumors in humans by loss-of-expression 
experiments [188]. ITGCN intensively expressed PTEN, whereas it was virtually absent in 
over 50 and 80% in seminomas and non-seminomas, respectively. Additionally, the same 
study showed LOH of the PTEN locus, and also revealed two inactivating mutations of PTEN. 
In the present series of TGCT no PTEN mutations were found. Taken together it seems that 
PTEN is commonly down-regulated in testicular cancer, but this cannot be explained by 




disturbed by altered expression of the PIK3CA. The facts that PIK3CA has a CpG island in 
the promoter, and that TGCT commonly include inactivated cancer critical genes through 
promoter hypermethylation, suggest the PIK3CA as an epigenetic target. Methylation studies 
of PIK3CA are currently in progress of investigation. 
 
The molecular basis of MPNSTs is poorly understood, although both loss of the NF1-gene 
and high levels of RAS activity have been described to be common hallmarks. Oncogenic 
mutations resulting in activated RAS are prevalent in 30% of all human cancers, however, it 
has not been detected in MPNSTs [55]. It is therefore suggested that the loss of NF1, which 
product usually accelerate the hydrolysis of active RAS-GTP to inactive RAS-GDP, is the 
cause of the functional up-regulation of the RAS signaling pathway. Not surprisingly, our 
results support this theory, as no KRAS mutations were identified. The present tumor series 
were from patients with the hereditary disease neurofibromatosis type 1 and from sporadic 
cases. The former carry a NF1 germ line mutation and it has been shown that both alleles are 
typically inactivated in their tumors. Therefore, it is interesting that the single BRAF mutation 
found was in a sporadic tumor that potentially does not have both NF1 alleles affected. The 
PIK3CA mutation was found in a tumor from a NF1 patient. The low frequencies may imply 
that these genes are not important in development or progression of MPNSTs. PTEN has been 
shown to be mutated in several cancer types, but in a previous study of 12 MPNSTs, Mawrin 
and co-workers failed to demonstrate mutations within the coding region of PTEN in 
MPNSTs [189]. They used the SSCP method, which is known to have somewhat reduced 
sensitivity, however taken together with the present results, we can conclude that mutations 






In the present study, we analyzed the promoter methylation of RASSF1A, which has been 
shown to be epigenetically inactivated in a variety of tumors, suggesting a major role for this 
tumor suppressor gene in cancer [68]. RASSF1A is shown to be inactivated predominantly by 
promoter methylation and rarely by somatic mutations. 
 
Several additional genes have been shown to be commonly methylated in colorectal cancer, 
including MGMT, MLH1, and RASSF2A [68,190-192]. In accordance with our result, the 
previously reported methylation frequencies of RASSF1A in colon ranges from 12-45% 
[65,193,194]. The wide frequency range might be due to inter-individual variation in scoring 
and interpretation of the methylation specific PCR (MSP) results, as well as the small number 
of samples included in some of the series. It has further been suggested that the RASSF1A 
inactivation in colorectal cancer is a late event, since methylation was rarely detected in 
benign adenomas (2%), versus more frequent in the carcinomas (16%) [195]. The timeline for 
RASSF1A inactivation in colorectal cancer needs further studies to be conclusive. 
 
About 25 different genes, known to be commonly methylated in various cancer types, have 
also been analyzed in TGCTs, and only a small number are found frequently methylated 
[161,164,196,197] (see figure 20 for genes analyzed in our group). Among the most 
frequently inactivated genes are MGMT, RASSF1A, APC, HIC1, and BRCA1. It is 
demonstrated that the nonseminoma group of TGCT show significantly more methylation 
than do the seminomas [121,164,197], ranging from 29-83% and 0-40%, respectively 
[161,196-198]. This is in concordance to our findings, resulting in 30% methylation of the 
nonseminomas and no methylation of the seminoma subgroup. Nonseminomas usually have 




demonstrated that promoter methylation of RASSF1A is associated with resistance to cisplatin 
[198], and might serve as a marker for the identification of resistant tumors. 
 
The methylation profile of MPNSTs remains mostly undescribed, as only few studies on 
promoter methylation have been done in this rare malignancy. The p16INK4A, is frequently 
silenced by promoter methylation or deletions in various cancer types. We initially showed 
that this gene is commonly deleted or rearranged in MPNST and thereby looses its 
expression, whereas gene methylation is not seen [142]. We and others have later confirmed 
the lack of methylation in larger series[142,143,199]. Similar results are reported for NF1 
[200,201]. Regarding RASSF1A, a recent report demonstrated a promoter methylation 
frequency of 18% in MPNST [202], substantially lower than what we found (47%). This 
might be due to different primer sets utilized for the MSP. However, most likely it reflects the 
low number (n = 17) of MPNSTs investigated in the Japanese study. 
 
Gene methylation in relation to genomic complexity is different among the three diseases. In 
colorectal carcinomas there is a general association between gene methylation and near 
diploidy, whereas in the TGCT model, methylated genes are characteristic to non-seminomas 
although all TGCT are in the triploid range. Finally, the MPNSTs show a wide range of 
genetic complexity, which is not related to gene methylation frequency. 
 
Mutually exclusive changes 
In nearly all cancer types it has been concluded that KRAS mutations are inversely associated 
with BRAF mutations, the exception being pancreatic cancer [203]. The mutual exclusivity is 




Mutations activates BRAF independent of RAS via the RAS-RAF-MEK-ERK signaling 
pathway, and previous reports provide strong support to the hypothesis that BRAF and KRAS 
mutations are equivalent in their tumorigenic effects. Furthermore, in a study published last 
year, it was suggested that PIK3CA mutations in colorectal cancer preferentially occur 
together with KRAS or BRAF mutations, suggesting a possible synergistic effect of the 
signaling pathways controlled by these in the development/progression of the disease [206]. 
The same trend could also be seen in our data set, although it was far from being statistically 
significant (see table 4). We found that mutations in PIK3CA were equally distributed 
between tumors with wild type and mutated KRAS and BRAF. 
 
In 2002, van Engeland and co-workers provided evidence for the interruption of RAS 
signaling in sporadic colorectal cancer by either genetic activation of KRAS or epigenetic 
silencing of RASSF1A [65], although they reported a small proportion (5%) of CRCs that had 
both RASSF1A methylation and KRAS mutations. Our findings, showing concomitant 
hypermethylation and activating mutations of the two genes, are in contrast to the Engeland 
study but in agreement with, Oliveira and co-workers whom did not find RASSF1A 
hypermethylation versus KRAS/BRAF mutations to be mutually exclusive events in MSI 
tumors [207]. Based on the existing literature, it seems not reasonable to conclude that 
methylation of RASSF1A and mutational activation of KRAS are functionally equivalent. To 
our knowledge, no studies have revealed whether RASSF1A inactivation is leading to 
activation of the RAS signaling pathway and hence providing an alternative pathway for 
affecting RAS signaling. Whether alterations of KRAS and RASSF1A are truly mutually 
exclusive events or not, must await clarification about the biological functions of RASSF1A. 
 




[208]. To our knowledge, no such connection has been studied in colorectal cancer, however, 
here we show that there is a strong inversely association between the two genes (P=0,002). 
Furthermore, the opposite result was obtained for PTEN and BRAF, showing an association 
for mutations in those genes. This is in accordance with the findings that KRAS mutations 
associate with MSS tumors, whereas mutations of BRAF and PTEN are more frequently found 
in MSI tumors. Additionally, somatic mutations in PTEN and TP53 are mutually exclusive in 
the stroma of breast carcinomas [209]. This seems to be the case for sporadic colorectal 
cancer as well, as we could also see an inversely association between the two genes. TP53 
activates the transcription of PTEN [83], hence negatively regulating the PI3K signaling 
pathway. Our results indicate that inactivation of the pathway can be achieved by the 
inactivation of either genes. 
 
No mutually exclusive events were found for PIK3CA in colorectal carcinomas, whereas for 
TGCT and MPNST there were found no mutually exclusive events regarding any of the genes 
(data not shown). 
 
Master keys in cancer 
In this thesis, there were found numerous alterations of KRAS, BRAF, PIK3CA, PTEN, and 
RASSF1A. We have shown that one or more of these are altered in more than ¾ of all 
colorectal carcinomas, affecting two signaling pathways, MAP-kinase and PI3K-AKT, which 
can be referred to as master keys in cancer. Epigenetically targeted master keys do exist, for 
instance p16INK4A and MGMT that are commonly inactivated by promoter methylation. 
Despite the identification of only few mutations in testis cancer, promoter methylation of the 




typical to development of TGCTs. The RASSF1A gene was indeed altered in a subgroup of all 
three diseases and summarizing this with similar findings in other cancer types suggest that 
we may look upon this gene as a key regulator of cancer. 
 
In MPNSTs, a small number of mutations were found in the genes analyzed. In parallel to this 
study we are currently analyzing NF1, which negatively regulates KRAS, and is expected to 
be commonly altered in MPNSTs. In this context, it will be interesting to find out if it turns 
out to be mutually exclusive in relation to KRAS, BRAF, and RASSF1A in either disease. 
Adding the NF1 data to the current data will further add information to how common one or 
more of the upstream MAPK- factors are altered across the three diseases. 
 
The two analyzed factors affecting the PI3K-AKT pathway show common mutations only in 
the colorectal model. However, these components have been shown important in other cancer 
types, and indeed methylation may again explain the absence of mutation in a subgroup of the 
samples. Therefore additional analyses must be made before conclusions can be drawn. 
Aiming to reveal master keys in cancer, there are some additional components that we are 
considering to investigate. In the PI3K-pathway, the proto-oncogene AKT1, which protect the 
cell from apoptosis and increases proliferation, is recently found to be inactivated by several 
upstream components. The tumor suppressor gene, PML, can inhibit the pathway by 
inactivating phosphorylated nuclear AKT1 [210]. Loss of PML in mice heterozygous of 
PTEN, accelerates tumor development resulting in invasive adenocarcinomas of the colon, 
whereas PTEN +/- mice displayed only pre-cancerous polyps. In addition to this, Krop and co-
workers has shown that HIN-1 (also known as SCGB3A1) is, among other things, also an 
inhibitor of AKT activation [211]. HIN-1 expression inhibited AKT1 phosphorylation induced 




methylation, which is also the case for testis cancer (see figure 20) [164]. It seems that the 
hypermethylation of HIN-1 to some degree coincide with the hypermethylation of RASSF1A 
in TGCTs, however, HIN-1 is additionally down-regulated in embryonic carcinomas, which is 
rarely seen for any other genes. Thus, we consider PML and HIN-1 in the context of upstream 
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Appendix I 
According to the nomenclature (Human Gene Nomenclature Committee), human genes 
should be written in italic capitals, and their gene products in capital without italic. 
Abbreviations mentioned twice or more in the text are listed here. 
 
AKT1   v-akt murine thymoma viral oncogene homolog 1 
APC   Adenomatous polyposis coli 
bp   base pairs 
BRAF   v-raf murine sarcoma viral oncogene homolog B1 
DNA   Deoxyribo nucleic acid 
CDK   Cyclin dependent kinase 
CDKN2A  Cyclin dependent kinase inhibitor 2A 
cDNA   complementary DNA 
CIMP   CpG island methylator phenotype 
CIN    Chromosomal instability 
CiS   carcinoma in situ 
CKI   Cyclin dependent kinase inhibitor 
CGH   Comparative genomic hybridization 
CRC   Colorectal cancer 
ddNTPs  dideoxyribonucleotide 
dNTP   deoxyribonucleotide (any of the four) 
EC   Embryonal carcinomas 
EGFR   Epidermal growth factor receptor 
FAP   Familial adenomatous polyposis coli 
GAP   GTPase activating protein 
GEF   Guanine nucleotide exchange factor  
GTP   Guanine triphosphate 
GRB2   Growth factor receptor-bound protein 2 
GSK-3β  Glycogen synthase kinase 3 beta 
HNPCC  Hereditary non-polyposis colorectal cancer 
ITGCN  Intratubular germ-cell neoplasia  




LOH   Loss of heterogozity 
MAPK  Mitogen-activated protein kinase 
MAPK1  Mitogen-activated protein kinase 1 
MAP2K1  Mitogen-activated protein kinase kinase 1 
MDM2  Transformed 3T3 cell double minute 2/ prev Mouse double minute 2 
MMR   Mismathc repair 
MLH1   mutL homolog 1 
MPNST  Malignant peripheral nerve sheath tumor 
MSH2   mutS homolog 2 
MSH6   mutS homolog 6 
MSI   Microsatellite instability  
MSP   Methylation-Specific PCR 
MST1   Macrophage stimulating 1 (hepatocyte growth factor-like) 
MTOR  Mammalian target of Rapamycin 
NF1   Neurofibromatosis 1 
NORE1  Ras association (RalGDS/AF-6) domain family 5 (RASSF5) 
OCT3/4  POU domain, class 5, transcription factor 1 (POU5F1) 
PCR   Polymerase Chain Reaction 
PIK3CA  Phosphoinositide-3-kinase, catalytic, alpha polypeptide 
PIP3    Phosphatidylinositol 3,4,5 triphosphate 
PIP2   Phosphatidylinositol 3,4 diphosphate  
PI3K   Phosphatidylinositol 3-kinase 
PTEN   Phosohatase and tensin homolog 
RASSF1A  Ras association (RalGDS/AF-6) domain family 1A 
RB1   Retinoblastoma 1 
RTK   Receptor tyrosine kinase 
SHC1   Src (homology 2 domain containing) transforming protein 1 
SMAD  Mothers against DPP homolog 
SOS   Son of sevenless homolog 1 
TGCT   Testicular germ cell tumor 
TGFβ1  Transforming growth factor β 
TP53   Tumor protein p53 




U   Units 
Wnt   Wingless-type 
  
Appendix II 
Primer sequences, annealing temperature and elongation time for the various genes analyzed. 
Abbreviations: Fwd, forward primer; Rev, reverse primer. For those exons with two forward primes; the first is 
used for the standard PCR, and the second for the sequence PCR.
Primer Annealing temperature (°C) Elongation time (sec)
KRAS
Exon 2 Fwd ACT GGT GGA GTA TTT GAT AG 50 30
Rev GTA TCA AAG AAT GGT CCT
Exon 3 Fwd ATAATAGCCAATCCTAA 50 45
Rev ATG GCA TTA GCA AAG
BRAF
Exon 11 Fwd TCC CTC TCA GGC ATA AGG TAA 60 45
Rev CGA ACA GTG AAT ATT TCC TTT GAT
Exon 15 Fwd TCA TAA TGC TTG CTC TGA TAG GA 58 45
Rev GGC CAA AAA TTT AAT CAG TGG A
RASSF1A
Unmethylated Fwd ATG TGT TGT GTA TTG TGT GGG G 62 30
Rev CCA CAA CAA CTA CAC TAC CCC
Methylated Fwd ACG CGT TGC GTA TCG CGC G 62 30
Rev CCG CGA CGA CTA CGC TAC C
PIK3CA
Exon 9 Fwd GAT TGG TTC TTT CCT GTC TCT G 58 30
Rev CCA CAA ATA TCA ATT TAC AAC CAT TG
Exon 20 Fwd AAG CCT CTC TAA TTT TGT GAC 54 30
Rev AAA CTC CAG TTT ACT TAC ACC
PTEN
Exon 1 Fwd CAG CCG TTC GGA GGA TTA 60/62 90
Rev ATA TGA CCT AGC AAC CTG ACC A
Exon 2 Fwd GTA CTT TAG TTC TGT GAT GTA TAA ACC GT 60 90
Rev CTG AAG TCC ATT AGG TAC GGT AA
Exon 3 Fwd ATG TTT GTG AGG GTC GAA TG 60 90
Rev GGA CTT CTT GAC TTA ATC GGT TTA G
Exon 4 Fwd 1 TTG AAA AAG GTG ATC GTT GG 60 90
Fwd 2 GGT GTG ATA ACA GTA TCT ACT TAA TAG
Rev ATT GTT ATG ACA GTA AGA TAC AGT CTA TCG
Exon 5 Fwd 1 GAC CTA TGC TAC CAG TCC GTA 60 90
Fwd 2 ATG CAA CAT TTC TAA AGT TAC CTA C
Rev ATG ATA TGA AAA TGG TAG CGT G
Exon 6 Fwd AAT GTA TAT ATG TTC TTA AAT GGC TAC GA 60 90
Rev TCA TAA ATA TAA TTT GGC TTC GAC TAC
Exon 7 Fwd TTG CTG ATA TTA ATC ATT AAA ATC GTT 60 90
Rev AAT AAT CAA GTC TTA AGA AAC GTT AAG G
Exon 8 Fwd AGT TGC ACT CAC CGT CCA 60 90
Rev ATG CAG CTT TTT TGA CGC T
Exon 9 Fwd GGC CTC TTA AAG ATC ATG TTT G 60 90
Rev CAC TTT TTA TAA AAC TGG AAT AAA ACG

























848 wt wt wt wt wt wt wt wt wt
854 wt wt wt wt - wt wt wt wt
884 wt T156C (D52D) wt wt - wt wt 1 A del (963-968) wt
887 wt wt wt wt wt wt wt wt wt
894I wt wt wt wt wt wt wt wt wt
896 wt wt wt wt wt wt wt wt wt
910 wt wt wt wt wt wt wt wt wt
912 wt wt wt wt wt wt wt wt wt
922 wt wt wt wt wt wt wt wt wt
946 wt wt wt wt wt wt wt wt wt
948 wt wt wt wt wt wt wt wt wt
953 wt wt wt wt wt wt wt wt wt
955 wt wt wt wt - wt wt wt wt
965 wt wt wt wt wt wt wt wt wt
988 wt wt wt wt wt wt? wt wt wt
1013 wt wt wt wt wt wt wt wt wt
1022 wt wt wt wt wt wt wt wt wt
1024 wt wt wt wt wt wt wt wt wt
1044 wt wt wt wt wt wt wt 4 bp del (950-953) wt
1046 wt wt wt wt wt wt wt wt wt
1047 wt wt wt - wt wt wt wt wt
1066 wt wt wt wt wt wt wt wt wt
1103 wt wt wt wt wt wt wt wt wt
1117 wt wt wt wt wt wt? wt wt wt
1121 wt wt wt wt wt wt wt wt wt
1124 wt wt wt wt wt wt wt wt wt
1132 wt wt wt wt wt wt wt wt wt
1141 2 bp del (GA) wt 1 T del (166-70) wt wt wt wt wt wt
1166 wt wt wt wt wt wt wt wt wt
1167 wt wt wt wt wt wt wt wt wt
1190 wt wt  1 T ins (166-70) wt wt wt 1A ins (795-800) wt wt
1193 wt wt wt wt wt wt wt wt wt
1194 wt wt wt wt wt wt wt wt wt
1197 wt wt wt wt wt wt wt wt wt
1268 wt wt wt wt wt T542C (L181P) wt 1 A del (963-968) wt
1273 wt wt wt wt - wt wt - wt
1287 wt nd wt nd nd wt nd nd wt
1294 wt wt wt wt wt wt wt wt wt
1296 wt wt wt wt wt wt wt wt wt
1314 wt wt wt wt T433A (F145I) wt wt wt wt
1326 wt wt wt wt - wt wt wt wt
1340 wt wt wt wt wt wt wt wt wt
1341 wt wt wt wt wt wt 1A del (795-800) wt wt
1342 wt wt wt wt - wt wt wt wt
1349 wt wt wt wt wt T542C (L181P) wt wt wt
1363 wt wt wt wt wt wt wt wt wt
1364 wt wt wt wt wt wt wt wt wt
1369 nd nd nd nd nd nd nd nd nd
1388A wt wt wt wt? wt wt wt wt wt
1388C wt wt wt wt - wt wt wt wt
1391 wt wt wt wt wt wt wt wt wt
868 wt wt wt wt wt wt wt wt wt
886 wt wt wt wt wt wt wt wt wt
904 wt wt wt wt wt wt wt wt wt
923 wt wt wt wt wt wt wt wt wt
927 wt wt wt wt wt wt wt wt wt
966 wt wt wt wt wt wt wt wt wt
974 wt wt wt wt wt wt wt wt wt
976 wt wt wt wt wt wt wt wt wt
980 wt wt wt wt 1 T del (267-70) wt wt 1 A del (963-968) wt
984 wt wt wt wt wt wt wt wt wt
1027 wt wt wt wt wt wt wt wt wt
1029 wt wt wt wt wt wt wt wt wt
1060 wt wt wt T242C (F81S) wt wt wt C895A (E299STOPP) wt
1069 wt wt wt wt G389A  (R130Q) wt wt T1022G (F1023V) wt




















848 wt wt wt wt A1634G (E545G) wt U
854 wt wt wt 3 bp del (kod 62) wt wt U
884 T1799A (V600E) wt wt wt wt wt U
887 wt wt G34T (G12C) wt A1637C (Q546P) wt M
894I wt wt  3 bp ins (TGG) wt wt wt U
896 wt wt wt wt wt wt M
910 wt wt wt wt wt wt U
912 wt wt G38A (G13D) wt G1633A (E545K) wt U
922 wt wt  G35T (G12 V) wt G1633A (E545K) wt U
946 wt wt wt wt wt wt U
948 wt wt  G34C (G12R) wt wt wt U
953 wt wt wt wt wt wt U
955 T1799A (V600E) wt wt wt wt wt U
965 T1799A (V600E) wt wt wt wt wt U
988 wt wt wt wt wt wt NS
1013 A1781G (D594G) wt wt wt wt wt U
1022 wt wt wt wt wt wt U
1024 wt wt G34T (G12C) wt wt wt U
1044 T1799A (V600E) wt wt wt wt wt U
1046 wt wt wt wt G1633A (E545K) wt U
1047 wt wt  G34C (G12A) / G40A (V14I) wt wt wt M
1066 wt wt wt wt wt wt M
1103 wt wt wt wt wt wt U
1117 wt wt wt wt wt wt U
1121 wt wt G34C (G12A) wt G1633A (E545K) wt M
1124 wt wt G34A (G12D) / G37A (G13D) wt wt wt NS
1132 wt wt G34T (G12V) wt G1624A (E542K) wt U
1141 wt wt wt wt wt wt U
1166 wt wt G37A (G13D) wt wt wt M
1167 wt wt wt wt wt wt M
1190 T1799A (V600E) wt wt wt wt wt M
1193 T1799A (V600E) wt wt wt wt A3140G (H1047R) U
1194 wt wt wt wt wt wt M
1197 wt wt wt wt wt wt NS
1268 T1799A (V600E) wt wt wt wt A3140T (H1047L) U
1273 T1799A (V600E) wt wt wt wt wt U
1287 wt wt wt wt nd nd ND
1294 wt G1406C (G469R) wt wt G1633A (E545K) wt U
1296 wt wt G37A (G13D) wt wt wt U
1314 wt wt wt wt wt wt U
1326 wt wt G37A (G13D) wt wt wt U
1340 wt wt wt wt wt wt NS
1341 T1799A (V600E) wt wt wt wt wt M
1342 wt wt wt wt wt wt U
1349 wt wt wt wt wt wt M
1363 wt wt G37A (G13D) wt wt wt U
1364 T1790A (L597Q) wt wt wt wt wt M
1369 wt nd G34A (G12D) wt nd nd ND
1388A wt wt wt wt wt wt M
1388C wt wt G37A (G13D) wt G1633A (E545K) wt M
1391 wt wt GAT G12D wt wt A3140G (H1047R) U
868 wt wt wt wt wt wt U
886 wt wt G34A (G12D) wt wt wt U
904 wt wt wt wt wt wt U
923 wt wt G37A (G13D) wt G1624A (542K) wt U
927 wt wt G34T (G12V) wt wt wt M
966 wt wt wt  A186C (Q61L) wt wt U
974 wt wt G34C (G12A) wt wt wt U
976 wt wt G34A (G12D) wt wt wt M
980 T1799A (V600E) wt wt wt wt wt U
984 T1799A (V600E) wt wt wt wt wt U
1027 wt wt G37A (G13D) wt wt wt U
1029 wt wt G34A (G12D) wt wt wt U
1060 wt wt wt wt wt A3073G (T1025A) M
1069 wt wt wt wt wt wt U


























30 wt wt wt wt wt wt wt wt wt
36 wt wt wt wt wt wt wt wt wt
53 wt wt wt wt wt wt wt wt wt
59 wt wt wt wt wt wt wt wt wt
70 wt wt wt wt wt wt wt wt wt
71 wt wt wt wt wt wt wt wt wt
75 wt C132T (G44G) wt wt wt wt nd wt wt
84 wt wt wt wt wt wt wt wt wt
85 wt wt wt wt wt wt wt wt wt
86 wt wt wt wt wt wt wt wt wt
88 wt wt wt wt wt wt wt wt wt
94 wt wt wt wt wt wt wt wt wt
95 nd nd nd nd nd nd nd nd nd
98 wt wt wt nd wt wt wt wt wt
102 wt wt wt wt wt wt wt wt wt
109 nd nd nd nd nd nd nd nd nd
110 wt wt wt wt wt wt wt wt wt
113 wt wt wt wt wt wt wt wt wt
118 nd nd wt nd nd nd nd nd nd
124 wt wt wt wt wt wt wt wt wt
127 wt wt wt wt wt? wt wt wt wt
130 wt wt wt wt wt wt wt wt wt
132 wt wt wt wt wt wt wt wt wt
133 wt wt wt wt wt wt wt wt wt
135 wt wt wt wt wt wt wt wt wt
136 wt wt wt wt wt? wt wt wt wt
137 wt nd wt wt wt wt wt wt wt
145 wt wt wt wt wt wt wt wt wt
146 wt wt wt wt wt wt wt wt wt
216 wt wt wt wt wt wt wt wt wt
307 wt wt wt wt wt wt wt wt wt
502 wt wt wt wt wt wt wt wt wt
564 wt wt wt wt wt wt wt wt wt
691 wt wt wt wt wt wt wt wt wt
696 wt wt wt wt wt wt wt wt wt
737 wt wt wt wt wt wt wt wt wt
738 wt wt wt wt wt wt wt wt wt
1017 wt wt wt wt wt wt wt wt wt
1113 wt wt wt wt wt wt wt wt wt
1282 wt wt wt wt wt wt wt wt wt
1545 wt wt wt wt wt wt wt wt wt
1692 wt wt wt wt wt wt wt wt wt
1740 wt wt wt wt wt wt wt wt wt
1748 wt wt wt wt wt wt wt wt wt
1838 wt wt wt wt wt wt wt wt wt
1863 wt wt wt wt wt wt wt wt wt
2201 wt wt wt wt wt wt wt wt wt
2110 wt wt wt wt wt wt wt wt wt
3493 wt wt wt wt wt wt wt wt wt





















30 wt wt wt wt wt wt U
36 wt wt wt wt wt wt U
53 wt wt wt wt wt wt U
59 wt wt wt wt wt wt U
70 wt wt wt wt wt wt M
71 wt wt G34/35T (G12L) wt wt wt U
75 wt wt wt wt wt nd U
84 wt wt wt wt wt wt M
85 wt wt wt wt wt wt U
86 wt wt wt wt wt wt U
88 wt wt wt wt wt wt U
94 wt wt wt wt wt wt U
95 nd nd nd nd nd nd nd
98 wt wt wt wt wt wt U
102 wt wt wt wt wt wt U
109 nd wt nd nd nd nd U
110 wt wt wt wt wt wt U
113 wt wt wt wt wt wt U
118 wt wt wt nd nd nd U
124 wt wt wt wt wt wt U
127 wt wt wt wt wt wt U
130 wt wt wt wt wt wt U
132 wt wt wt wt wt wt U
133 G1780A  (D594N) wt wt wt wt wt U
135 wt wt wt wt wt wt U
136 wt wt wt wt wt wt M
137 wt wt wt wt wt wt U
145 w wt wt wt wt wt U
146 wt wt wt wt wt wt U
216 wt wt wt wt wt wt M
307 wt wt wt wt wt wt M
502 wt wt wt wt wt wt U
564 wt wt wt wt wt wt U
691 wt wt wt wt wt wt U
696 wt wt wt wt wt wt U
737 wt wt wt wt wt wt U
738 wt wt wt wt wt wt M
1017 wt wt wt wt wt wt U
1113 wt wt  G34A (G12S) wt wt wt U
1282 wt wt wt wt wt wt M
1545 wt wt wt wt wt wt U
1692 wt wt wt wt wt wt U
1740 wt wt wt wt wt wt U
1748 wt wt wt wt wt wt U
1838 wt wt wt wt wt wt U
1863 wt wt wt wt wt wt U
2201 wt wt wt wt wt wt U
2110 wt wt wt wt wt wt M
3493 wt wt wt wt wt wt U


























650-90P wt wt wt wt wt wt wt wt wt
2362-90-1 wt wt wt wt wt wt wt wt wt
2367-90-1 wt wt wt wt wt wt wt wt wt
753-92P-1 wt wt wt wt wt wt wt wt wt
32-94R wt wt wt wt wt wt wt wt wt
1615-94P wt wt wt wt wt wt wt wt wt
2406-94P wt wt wt wt wt wt wt wt wt
1046-95P wt wt wt wt wt wt wt wt wt
1944-95P wt wt wt wt wt wt wt wt wt
763-91P wt wt wt wt wt wt wt wt wt
3420-95P wt wt wt wt wt wt wt wt wt
246-96P wt wt wt wt wt wt wt wt wt
11-AEL wt wt wt wt wt wt wt wt wt
12-HK wt wt wt wt wt wt wt wt wt
13-EEO wt wt wt wt wt wt wt wt wt
14-GP wt wt wt wt wt wt wt wt wt
3-HPK wt wt wt wt wt wt wt wt wt
5-GKH wt wt wt wt wt wt wt wt wt
6-OMN wt wt wt wt wt wt wt wt wt
7-GM wt wt wt wt wt wt wt wt wt
8-EMA wt wt wt wt wt wt wt wt wt
9-MO wt wt wt wt wt wt nd wt wt
T85-6544 wt wt wt wt wt wt wt wt wt
T84-8124 wt wt wt wt wt wt wt wt wt
T89-3925 wt wt wt wt wt wt wt wt wt
T91-10391 wt wt wt wt wt wt wt wt wt
T92-10261 wt wt wt wt wt wt wt wt wt
T95-13713 wt wt wt wt wt wt wt wt wt
T95-2487 wt wt wt wt wt wt wt wt wt
T97-2719 wt wt wt wt wt wt wt wt wt
T97-7036 wt wt wt wt wt wt wt wt wt






















650-90P wt wt wt wt wt wt NS
2362-90-1 wt wt wt wt wt wt U
2367-90-1 wt wt wt wt wt wt U
753-92P-1 wt wt wt wt wt wt M
32-94R wt wt wt wt wt wt U
1615-94P wt wt wt wt wt wt M
2406-94P A1742G (N581S) wt wt wt wt wt U
1046-95P wt wt wt wt wt wt U
1944-95P wt wt wt wt wt wt M
763-91P wt wt wt wt wt wt U
3420-95P wt wt wt wt wt wt U
246-96P wt wt wt wt wt wt M
11-AEL wt wt wt wt wt wt M
12-HK wt wt wt wt wt wt U
13-EEO wt wt wt wt wt wt U
14-GP wt wt wt wt wt wt M
3-HPK wt wt wt wt wt wt M
5-GKH wt wt wt wt wt wt U
6-OMN wt wt wt wt wt wt M
7-GM wt wt wt wt wt wt M
8-EMA wt wt wt wt wt A3140G (H1047R) U
9-MO wt wt wt wt wt nd NS
T85-6544 wt wt wt wt wt wt U
T84-8124 wt wt wt wt wt wt M
T89-3925 wt wt wt wt wt wt U
T91-10391 wt wt wt wt wt wt M
T92-10261 wt wt wt wt wt wt U
T95-13713 wt wt wt wt wt wt U
T95-2487 wt wt wt wt wt wt U
T97-2719 wt wt wt wt wt wt M
T97-7036 wt wt wt wt wt wt M




Patient MSI status Localisation Gender Age Ploidi TP53 status APC status Dukes' stage Differentiation
848 MSI Rectum Male 41 1,9 - Mut B Medium
854 MSI Right Female 74 1,0 Wt Mut A Low
884 MSI Right Female 90 1,0 - Mut B Medium
887 MSS Rectum Female 82 1,1 Wt Wt B High
894I MSI Right Male 80 1,0 - Mut B Medium
896 MSS Rectum Female 71 1,1 Mut Wt C Medium
910 MSI Right Female 65 1,0 Wt Mut B High
912 MSI Left Female 66 1,0 - Mut B Low
922 MSS Left Male 71 1,6 Wt Wt D Medium
946 MSS Left Male 77 1,0 Wt Wt B Medium
948 MSS Rectum Female 61 1,4 Wt Wt B High
953 MSS Rectum Male 68 1,5 Mut Wt B Medium
955 MSI Right Female 84 1,0 - Mut B Medium
965 MSI Left Female 67 1,0 - Wt B Low
988 MSI Right Female 66 1,0 Wt Wt B Low
1013 MSS Rectum Female 66 1,5 Mut Wt B Medium
1022 MSI Rectum Male 33 1,0 Wt Mut C Low
1024 MSS Left Female 60 1,0 Wt Wt C Medium
1044 MSI Rectum Female 63 1,1 - Wt A Medium
1046 MSS Left Male 66 1,5 Mut Mut D Medium
1047 MSI Rectum Male 70 1,0 - Wt C Medium
1066 MSI Left Female 41 1,0 Wt Wt C Medium
1103 MSS Left Female 62 1,0 Wt Wt B Medium
1117 MSI Right Male 78 1,0 - Mut C Medium
1121 MSS Left Male 71 1,0 Mut Wt B Medium
1124 MSS Rectum Male 73 1,4 Wt Mut C Medium
1132 MSI Right Female 92 1,0 - Wt D Medium
1141 MSI Right Female 76 1,0 - Mut D Medium
1166 MSS Left Male 77 1,7 Wt Wt B Medium
1167 MSS Left Male 73 3,0 Mut Mut C Medium
1190 MSI Right Male 67 1,0 Wt Mut C Medium
1193 MSI Right Female 69 1,0 Wt Wt C Low
1194 MSS Left Male 44 1,6 Mut Wt C Medium
1197 MSS Left Male 71 1,2 Mut Wt C Medium
1268 MSI Right Male 71 1,0 - Mut B Low
1273 MSI Right Female 68 1,0 - Mut B Medium
1287 MSS Rectum Male 77 2,1 Mut Mut B Medium
1294 MSS Left Male 73 1,9 Wt Mut C Low
1296 MSS Left Male 76 1,7 Mut Mut B Medium
1314 MSI Right Female 62 1,0 Wt Mut C Low
1326 MSI Left Male 61 1,0 - Mut B Medium
1340 MSS Rectum Male 51 1,2 Mut Mut C Medium
1341 MSI Right Female 89 1,0 - Mut B Medium
1342 MSI Right Male 49 1,0 Mut Mut B Medium
1349 MSI Right Female 79 2,0 Wt Mut D Low
1363 MSI Right Male 70 1,0 Wt Wt A Medium
1364 MSS Rectum Female 60 1,4 Wt Mut B Medium
1369 MSS left Female 82 1,5 Wt Wt B Low
1388 MSI left Female 61 1,0 - Wt D Low
1388C MSI left Female 61 1,0 - Wt D Low
1391 MSS Rectum Female 71 1,9 Mut Mut B Medium
868 MSS Left Male 64 1,9 Wt Mut B Medium
886 MSS Left Female 61 1,0 Wt Wt C Medium
904 MSS Left Male 78 1,6 Mut Wt B Medium
923 MSS Right Male 85 1,0 Wt Wt C High
927 MSS Rectum Female 73 1,7 Mut Wt B Medium
966 MSS Rectum Male 61 1,5 Mut Wt A Medium
974 MSS Right Male 73 2,1 Mut Mut B Medium
976 MSS Rectum Male 58 1,0 Wt Wt B Medium
980 MSI Right Female 75 1,0 Wt Mut C Medium
984 MSI Right Female 88 1,0 Wt Mut C Low
1027 MSS Rectum Male 79 1,6 Mut Wt B Medium
1029 MSS Right Male 83 1,4 Wt Wt C Medium
1060 MSS Left Male 70 1,15 Wt Wt A Medium
1069 MSS Right Male 74 1,0 Wt Wt B Low










70 Non seminoma Mixed
71 Seminoma Seminoma
75 Seminoma Seminoma
84 Non seminoma Immature teratoma
85 Seminoma Seminoma
86 Non seminoma Teratoma
88 Non seminoma Embr.carc/Teratoma
94 Seminoma Seminoma
95 Seminoma Seminoma
98 Non seminoma Teratoma
102 Non seminoma Immature teratoma
109 Seminoma Seminoma
110 Non seminoma Embryonal carcinoma
113 Seminoma Seminoma
118 Seminoma Seminoma






136 Non seminoma Mixed
137 Non seminoma Embryonal carcinoma
145 Non seminoma Embryonal carcinoma
146 Non seminoma Yolk sac tumor
216 Non seminoma Yolk sac tumor
307 Non seminoma Yolk sac tumor
502 Non seminoma Embryonal carcinoma
564 Non seminoma Embryonal carcinoma
691 Non seminoma Teratoma
696 Non seminoma Teratoma
737 Seminoma Seminoma
738 Non seminoma Yolk sac tumor
1017 Non seminoma Embryonal carcinoma
1113 Seminoma Seminoma
1282 Non seminoma Teratoma
1545 Non seminoma Embryonal carcinoma
1692 ITGCN ITGCN
1740 Non seminoma Embryonal carcinoma
1748 Seminoma Seminoma
1838 Non seminoma Embryonal carcinoma
1863 ITGCN ITGCN
2201 Non seminoma Teratoma
2110 Non seminoma Yolk sac tumor
3493 ITGCN ITGCN
3879 ITGCN ITGCN
TGCT
Appendix IV 
 
 
 
Patient NF1-status Kjønn
650-90P Wt Female
2362-90-1 Mut Female
2367-90-1 Mut Male
753-92P-1 Mut Female
32-94R Mut Male
1615-94P Wt Female
2406-94P Wt Female
1046-95P Wt Female
1944-95P Mut Female
763-91P Mut Female
3420-95P Wt Male
246-96P Wt Male
11-AEL Wt Male
12-HK Mut Female
13-EEO Wt Male
14-GP Mut Male
3-HPK Mut Male
5-GKH Wt Female
6-OMN Mut Male
7-GM Mut Female
8-EMA Mut Female
9-MO Mut Female
T85-6544 Mut Male
T84-8124 Mut Male
T89-3925 Wt Male
T91-10391 Mut Female
T92-10261 Mut Male
T95-13713 Wt Female
T95-2487 Mut Male
T97-2719 Mut Male
T97-7036 Mut Male
T98-13182 Mut Female
MPNST
